<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005365.pub2" GROUP_ID="ANAESTH" ID="286604071811271923" MERGED_FROM="" MODIFIED="2008-09-01 21:23:13 +0200" MODIFIED_BY="Karen Hovhannisyan" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.5&lt;/p&gt;&lt;p&gt;Old title: Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 21:20:46 +0200" NOTES_MODIFIED_BY="Karen Hovhannisyan" REVIEW_NO="101" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-09-01 21:23:13 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TITLE>Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts</TITLE>
<CONTACT MODIFIED="2008-09-01 21:23:13 +0200" MODIFIED_BY="Karen Hovhannisyan"><PERSON ID="18174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Ratilal</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>bratilal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 963047176</PHONE_1><FAX_1>+351 218841052</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-01 21:23:13 +0200" MODIFIED_BY="Karen Hovhannisyan"><PERSON ID="18174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Ratilal</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>bratilal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 963047176</PHONE_1><FAX_1>+351 218841052</FAX_1></ADDRESS></PERSON><PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>João</FIRST_NAME><LAST_NAME>Costa</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Neurologist</POSITION><EMAIL_1>joaoncosta@sapo.pt</EMAIL_1><EMAIL_2>joaoncosta@sapo.pt</EMAIL_2><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina Lisboa</ORGANISATION><ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 91 7532125</PHONE_1><PHONE_2>+ 351 21 7973453</PHONE_2><FAX_1>+ 351 21 7819688</FAX_1></ADDRESS></PERSON><PERSON ID="6111" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cristina</FIRST_NAME><LAST_NAME>Sampaio</LAST_NAME><EMAIL_1>movementdisord@fm.ul.pt</EMAIL_1><EMAIL_2>movementdisord@mail.telepac.pt</EMAIL_2><ADDRESS><DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT><ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION><ADDRESS_1>Hospital de Santa Maria</ADDRESS_1><ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+ 351 21 797 34 53</PHONE_1><FAX_1>+ 351 21 780 2129</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-01 21:23:13 +0200" MODIFIED_BY="Karen Hovhannisyan" NOTES="&lt;p&gt;Minor update: 15/05/06&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="15" MONTH="5" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="5" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="1" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-01 20:59:00 +0200" MODIFIED_BY="Karen Hovhannisyan"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Therapeutics Institute, Lisbon Faculty of Medicine</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-01 21:20:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<SUMMARY>
<TITLE>A review of the medical literature for evidence of whether the use of intravenous antibiotics, or devices impregnated with antibiotics, reduce the risks of infection during the surgical placement of catheters for the drainage of excess fluid from the brain</TITLE>
<SUMMARY_BODY>
<P>An intracranial ventricular shunt is a device (catheter/tube) used to drain an excess of cerebrospinal fluid from the brain. (Cerebrospinal fluid is a clear body fluid released into the subarachnoid space; the subarachnoid space surrounds the brain and the spinal cord.) Patients with intracranial ventricular shunts are prone to infection. Some doctors give either antibiotic drugs or use antibiotic-impregnated devices to reduce the risk of infection. Our review included randomized controlled trials that compared the incidence of shunt infection in patients who were given preventive antibiotic therapy with those who did not receive these drugs. We also included trials comparing antibiotic-impregnated shunt systems with those who received non-antibiotic impregnated shunts. We included seventeen trials in our review. Although the available data does not provide much detail on mortality or the adverse events caused by antibiotics (an adverse event is an incident in which harm resulted to a person receiving the health care) it does support the use of preventative systemic prophylactic antibiotics for the first 24 hours postoperatively following an intracranial ventricular shunt operation or the use of antibiotic-impregnated catheters. However this data was obtained from an intermediary outcome which is the rate of shunt infections. Therefore although the evidence suggests that the use of antibiotics is beneficial in reducing the incidence of shunt infection more research is needed to confirm their benefit. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Systemic antibiotics and antibiotic-impregnated shunt systems are often used to prevent shunt infection.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of either prophylactic systemic antibiotics or antibiotic-impregnated shunt systems for preventing infection in patients who underwent surgical introduction of intracranial ventricular shunts. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS and the meeting proceedings from the American Association of Neurological Surgeons and from the European Association of Neurosurgical Societies, until June 2005. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included randomized or quasi-randomized controlled trials comparing the use of prophylactic antibiotics (either systemic or antibiotic-impregnated shunt systems) in intracranial ventricular shunt procedures with placebo or no antibiotics. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors appraised quality and extracted data independently.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included seventeen trials with overall 2134 participants. We performed two separate meta-analyses: one that evaluated the use of systemic prophylactic antibiotics and another that evaluated the use of antibiotic-impregnated systems. All studies included shunt infection in their primary outcome. </P>
<P>We could not analyse all-cause mortality regarding systemic antibiotics due to lack of data. No significant differences were found (odds ratio (OR): 1.47, 95% confidence intervals (CI) 0.83 to 2.62) for this outcome regarding the use of antibiotic-impregnated catheters compared with standard ones. The use of systemic antibiotic prophylaxis and the use of antibiotic-impregnated catheters were associated with a decrease in shunt infection (OR: 0.52, 95% CI 0.36 to 0.74 and OR: 0.21, 95% CI 0.08 to 0.55 respectively). We found no significant benefit for shunt revision in both meta-analyses that evaluated systemic antibiotics and impregnated-shunt systems. We found no significant differences between the subgroups evaluated: type of shunt (internal/external, ventriculoperitoneal/ventriculoatrial), age and duration of the administration of antibiotics. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>We could demonstrate a benefit of systemic prophylactic antibiotics for the first 24 hours postoperatively to prevent shunt infection, regardless of the patient's age and the type of internal shunt used. The benefit of its use after this period remains uncertain. However this data derives from the rate of shunt infection, which is an intermediary outcome. Future trials should evaluate the effectiveness of different regimens of systemic antibiotics rather than placebo, and should include all-cause mortality, shunt revision and adverse events as additional outcomes. Evidence suggests that antibiotic-impregnated catheters reduce the incidence of shunt infection although more well-designed clinical trials testing the effect of antibiotic-impregnated shunts are required to confirm their net benefit.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-01 21:20:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<BACKGROUND>
<P>Intracranial ventricular shunts are silastic tubes that divert a pathologic excess of cerebrospinal fluid (CSF) from the ventricles of the brain either to the exterior (external ventricular shunts), or to other body cavities (internal ventricular shunts), where normal physiologic processes can absorb the fluid. Without these shunts, fluid can build up in spaces of the brain and cause damage to the brain tissue. External shunts are used in an emergency or potentially reversible hydrocephalus situations. Recommendations concerning routine changing of ventricular catheters in order to reduce the risk of infection remain controversial. Internal ventricular shunts are implanted for the life of the patient but as many as 30% of these will need to be replaced or modified at some point. </P>
<P>Ventriculo-peritoneal shunts are the most commonly used internal shunts. Ventriculo-atrial shunts, (which pass fluid to the superior cava), are an option when abdominal abnormalities are present. Ventriculo-pleural shunts are another type of intracranial shunt. They may be used when other routes are not indicated. Placement of the distal end of the catheter has been reported in the gall bladder, ureter and bladder. Approximately 40 per 100,000 of people in the United States of America have shunts in place; the majority of these are children (<LINK REF="REF-Moss-1991" TYPE="REFERENCE">Moss 1991</LINK>). <BR/>
<BR/>The most significant complication resulting from intracranial ventricular shunt is infection. This affects from 1.5 to 38% of patients (<LINK REF="REF-Claus-2004" TYPE="REFERENCE">Claus 2004</LINK>). Age seems to be an important risk factor, with infection rates amongst young children of up to 20% (<LINK REF="REF-Bondurant-1995" TYPE="REFERENCE">Bondurant 1995</LINK>). It is thought that younger people have higher levels of morbidity due to infection, which is of concern. The presenting symptoms of shunt infection are variable, they may be related to the type of infective organism and also age-dependent. Shunt infection may be associated with increased mortality; increased risk of seizure disorders; and decreased intellectual performance. Treatment usually requires prolonged hospitalization for antibiotic administration and repeated surgery. </P>
<P>It is not clear what mechanism predisposes a shunt to infection (<LINK REF="REF-Borges-1982" TYPE="REFERENCE">Borges 1982</LINK>), since the device is recognized by the body as a foreign body. It is likely that the initial step in this process is bacterial colonization of the device during the surgical procedure. There is a reduction of normal defence mechanisms and local immunity caused by the foreign body, and from a complex and effective adherence process between bacteria and the device. These have a role in postoperative device-related infections. However, the benefit of systemic antibiotic prophylaxis is not generally accepted and its use is frequently a matter of discussion. In fact, some authors found no relationship between infection and the use of systemic prophylactic antibiotics (<LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="REF-Stenager-1986" TYPE="REFERENCE">Stenager 1986</LINK>). A meta-analysis performed by Langley et al. showed a 50% reduction in the risk of infection for internal shunts if perioperative prophylaxis was used (<LINK REF="REF-Langley-1993" TYPE="REFERENCE">Langley 1993</LINK>); that is, if prophylaxis was maintained for 24 to 72 hours after surgery. Another meta-analysis (<LINK REF="REF-Haines-1994" TYPE="REFERENCE">Haines 1994</LINK>) focused on data that were strongly correlated with a high baseline infection rate. The benefit associated with antibiotics was no longer apparent when the baseline infection was at or below about 5%. These studies did not comprise an extensive and comprehensive review of the literature and the papers included were searched until 1990 and 1993 respectively. </P>
<P>Nevertheless, continuous prophylactic antibiotics are widely administered to patients with external ventricular drains (EVD), despite a paucity of data supporting their use There is no evidence of a difference in the rate of CSF infection in patients with EVD who received continuous prophylactic antibiotics for the duration of drain placement, compared with those who received only periprocedural dosing (started immediately before placement of the drain and continued for three or fewer doses, or continued for less than 24 hours) (<LINK REF="REF-Alleyne-2000" TYPE="REFERENCE">Alleyne 2000</LINK>). The development and growing use of the newly developed antibiotic-impregnated shunt systems also demand an evidence-based investigation of their effectiveness and safety when compared with standard shunt systems. </P>
<P>In the light of increasing concern about antibiotic resistance (<LINK REF="REF-Frazee-1988" TYPE="REFERENCE">Frazee 1988</LINK>), it is critical to search and analyse the evidence of effectiveness and safety of the use of prophylactic systemic antibiotics compared with placebo or no antibiotics; of the use of periprocedural versus continuous antibiotics; and of the use of antibiotic-impregnated systems compared with standard systems for surgically introduced intracranial ventricular shunts. </P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-09-01 21:00:39 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>We examined the following hypotheses:</P>
<OL>
<LI>The incidence of shunt infection is less frequent with administration of systemic antibiotics beginning previously or at the time of the surgical procedure.</LI>
<LI>The incidence of shunt infection is less frequent when antibiotic-impregnated shunt systems are used, considering that the eventual regimen of systemic antibiotics applied is the same.</LI>
</OL>
<P>We tested these hypotheses by performing a literature review with the following objectives:</P>
<SUBSECTION>
<HEADING LEVEL="2">Primary objective </HEADING>
<P>Our primary objective was to establish the effectiveness and safety of the use of prophylactic antibiotics, whether systemic or catheter-impregnated, for intracranial ventricular shunts.</P>
<P>We performed independent analyses for systemic antibiotics and antibiotic-impregnated systems. Within each of the former analyses, we also performed separate analyses for external and internal intracranial shunts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary Objectives </HEADING>
<P>We performed the following subgroup analyses if sufficient relevant information was available:</P>
<OL>
<LI>To determine the differences in the risk of developing an infection of external ventricular shunts versus internal ventricular shunts.</LI>
<LI>To determine the differences in the risk of developing an infection of ventriculoperitoneal shunts versus ventriculoatrial shunts.</LI>
<LI>To determine the differences in the risk of developing an infection in children versus all ages.</LI>
<LI>To determine the differences in the risk of developing an infection in using periprocedural antibiotics versus continuous antibiotics.</LI>
</OL>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<SELECTION_CRITERIA MODIFIED="2008-09-01 21:01:17 +0200" MODIFIED_BY="Karen Hovhannisyan">
<CRIT_STUDIES>
<P>We included randomized controlled trials (RCTs) comparing the use of prophylactic antibiotics in intracranial ventricular shunts procedures with placebo or the standard treatment. </P>
<P>We also included trials with poor allocation concealment (quasi-randomized). </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included patients of any age with any type of intracranial ventricular cerebrospinal fluid shunt surgical procedure. </P>
<P>We excluded patients with either suspected or confirmed pre-existing infection. We defined infection according to the study investigator's criteria. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-09-01 21:00:56 +0200" MODIFIED_BY="Karen Hovhannisyan">
<OL>
<LI>Systemic administration of any antibiotic(s), at any dosage, beginning previously or at the time of the surgical procedure and prolonged for any length of time, compared with placebo or no antibiotics.</LI>
<LI>Employment of antibiotic-impregnated shunt systems compared with standard shunt systems.</LI>
</OL>
<P>We excluded trials comparing different antibiotics; different dosages; route of administration; or differences in timing or duration of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-01 21:01:17 +0200" MODIFIED_BY="Karen Hovhannisyan">
<OL>
<LI>All-cause mortality (death resulting from central nervous system infection or other cause mortality including progression of the primary disease process and multi-system failure).</LI>
<LI>Shunt infection (evidence of infection in one or more of the following: shunt equipment, overlying wound, CSF or site related to distal drainage route: organism identification by tissue cultures from material in or around the shunt, or by cultures from fluid or CSF drawn from the shunt system itself).</LI>
<LI>Shunt revision (part or all of a shunt system).</LI>
<LI>Adverse events of antibiotics: number of patients with any adverse event, serious adverse events other than death, allergic reactions and other non-allergic adverse effects. We considered the original author's categorization of the adverse events whenever stated it.</LI>
</OL>
<P>We considered disability, cognitive function and quality of life as additional outcome measures, whatever the management used in the individual trials. In addition, we also considered length of hospital stay as an additional outcome measure.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<ELECTRONIC_SEARCHES MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 3, 2005); MEDLINE (January 1966 to June 10th 2005, PubMed); EMBASE (1980 to June 10th 2005, SilverPlatter); and LILACS (1982 to June 10th 2005, Virtual Health Library).</P>
<P>Our search strategy for MEDLINE and CENTRAL will be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We combined this search with all three stages of the optimal search strategy devised for The Cochrane Collaboration (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). We modified this search strategy for EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and LILACS (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-01 21:02:54 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>We screened titles, keywords and abstracts of the citations downloaded from the electronic searches.</P>
<P>We obtained full copies of reports of potentially suitable trials for further assessment.</P>
<P>We checked reference lists of located trials and review articles focusing on intracranial ventricular shunts. We also electronically searched meeting proceedings from the American Association of Neurological Surgeons (AANS) (1997 to June 10th 2005) and handsearched the abstracts from the meeting proceedings of the European Association of Neurosurgical Societies (EANS) (1995 to 2003).</P>
<P>We contacted researchers active in the field, for information regarding unpublished trials.</P>
<P>We also contacted authors of published trials for further information and unpublished data.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two authors (BORL, JOAC) independently assessed the studies identified by the search strategy. We identified potentially suitable trials for the review, according to the criteria outlined above. We resolved disagreements by discussion with a third author (SCRI). </P>
<P>We independently assessed the full papers for the type of participants; the type and dose of antibiotic used; the methodological quality; the number of patients excluded or lost to follow-up; and the outcome measures stated in the protocol. We searched for sources of bias. </P>
<P>We abstracted eligible data using standardized data extraction forms. We cross-checked all data abstracted for accuracy before combining for analysis. We expressed the results as binary data. If data on disability, cognitive function, quality of life or length of hospital stay were available we provided a descriptive analysis. Additionally, if appropriate, we treated results as dichotomous, or handled them as continuous variables. When information on these outcomes was not available we reported their absence. </P>
<P>We analysed clinical heterogeneity qualitatively, taking into account factors such as the studied population, surgical procedure and technique. We made the decision to perform a meta-analysis based on absence of considerable clinical heterogeneity. We provided a descriptive summary of the results where the outcome data from different studies cannot be combined. </P>
<P>We performed statistical analyses using the statistical software provided by the Cochrane Collaboration (<LINK REF="REF-RevMan-4.2" TYPE="REFERENCE">RevMan 4.2</LINK>). We investigated for statistical heterogeneity between trial results using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). </P>
<P>We used pooled summary estimates appropriate to the given data. We also used random-effects models or fixed-effect models as appropriate. </P>
<P>The number of patients who must be treated to prevent one adverse outcome (number needed to treat (NNT)) is a widely used measure. However, the NNTs derived from meta-analysis may be misleading because of the variation in the event rates in trials; differences in the outcomes considered; effects of secular trends on disease risk, and differences in clinical setting (<LINK REF="REF-Smeeth-1999" TYPE="REFERENCE">Smeeth 1999</LINK>). There is debate concerning methods for calculating the NNTs from results of systematic reviews. We have calculated the NNTs from meta-analysis estimates and have not treated the data as if they arose from a single trial since the latter approach is more prone to bias (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>). We assessed the difference between subgroups by calculating a two-tailed z-score using the following formulae for binary data: </P>
<P>z = (lnOR1 - lnOR2 ) / &#8730;(var[lnOR1] + var[lnOR2]) where OR1 and OR2 are the combined odds ratios from each subgroup and var is the variance of each which was calculated from the 95% confidence intervals (<LINK REF="REF-Fleiss-1993" TYPE="REFERENCE">Fleiss 1993</LINK>). </P>
<P>Since there is evidence that the quality of allocation concealment particularly affects the results of studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), two authors (BORL, JOAC) scored this quality on the scale used by Schulz (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) as described below: </P>
<P>A = trials deemed to have taken adequate measures to conceal allocation (that is central randomization; serially numbered, opaque, sealed envelopes; or other description that contained elements convincing of concealment). </P>
<P>B = trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories. </P>
<P>C = trials in which concealment was inadequate (such as alternation or reference to case record numbers or to dates of birth). </P>
<P>We performed a sensitivity analysis of class A trials. We used the graphical test proposed by Egger (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) to evaluate publication bias. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-01 21:18:40 +0200" MODIFIED_BY="Karen Hovhannisyan">
<STUDY_DESCRIPTION MODIFIED="2008-09-01 21:09:25 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>(See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>)</P>
<P>We identified twenty-one potentially eligible trials, including one duplicate citation (<LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK>). We excluded three studies (<LINK REF="STD-Epstein-1982" TYPE="STUDY">Epstein 1982</LINK>; <LINK REF="STD-Shapiro-1986" TYPE="STUDY">Shapiro 1986</LINK>; <LINK REF="STD-Siqueira-1987" TYPE="STUDY">Siqueira 1987</LINK>), our reasons are listed in the table of 'Characteristics of Excluded Studies'.</P>
<P>We included seventeen trials in this systematic review. We were able to perform two meta-analyses: one which evaluated the benefit of systemic prophylactic antibiotics for ventricular shunts included fifteen trials (<LINK REF="STD-Bayston-1975" TYPE="STUDY">Bayston 1975</LINK>; <LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Yogev-1985" TYPE="STUDY">Yogev 1985</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>). The second meta-analysis investigated the effectiveness of antibiotic-impregnated catheters compared with standard ones, and included two trials (<LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK>; <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK>). All these trials had a randomized parallel design and were published between 1975 and 2003.</P>
<P>Entry criteria did not differ considerably between the included trials. Most trials enrolled patients undergoing a CSF shunting procedure, whether shunt insertion or shunt revision. The exceptions were the <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK> and <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK> trials which included only patients receiving their first shunt implantation. There were eight trials that included only children (<LINK REF="STD-Bayston-1975" TYPE="STUDY">Bayston 1975</LINK>; <LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>, <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>;<LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Yogev-1985" TYPE="STUDY">Yogev 1985</LINK>). Most trials evaluated patients who were given internal ventricular shunts, except <LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>, (which evaluated a subgroup of patients given external ventricular drains) and <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK> (which evaluated the effect of antibiotic-impregnated catheters in external shunt procedure).</P>
<P>Shunt infection was a primary outcome in all included trials and was always based on clinical and laboratory grounds (CSF cell count/biochemistry suggestive of infection and/or positive CSF culture). From the trials that evaluated the effect of systemic antibiotics, only two reported data on outcomes of its safety and tolerability (<LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>).</P>
<P>In ten trials (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>, <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>; <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK>) patients were generally well-matched within studies between the treatment and control arms for demographics, etiology of hydrocephalus, type of shunting and duration of the operation. The remaining trials did not describe the characteristics of the population included in each group.</P>
<P>Description of withdrawals and dropouts sufficient to determine the number of patients in each treatment group entering and completing the trial were available in only four trials (<LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-01 21:14:08 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>(See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>)<B>
<BR/>
</B>
<BR/>All studies stated that they randomized patients between the treatment and control options. The precise method of randomization and details of concealment of allocation was described and considered adequate in eight trials (<LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>); considered unclear in seven trials (<LINK REF="STD-Bayston-1975" TYPE="STUDY">Bayston 1975</LINK>; <LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK>; <LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK>; <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Yogev-1985" TYPE="STUDY">Yogev 1985</LINK>), and considered inadequate in two trials (<LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>).</P>
<P>From the 15 studies evaluating the effect of the systemic antibiotics there were seven studies double blinded throughout using identical appearance interventions (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>). Two other studies were also placebo controlled (<LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Yogev-1985" TYPE="STUDY">Yogev 1985</LINK>); while the remaining six studies used no antibiotics as a control group (<LINK REF="STD-Bayston-1975" TYPE="STUDY">Bayston 1975</LINK>; <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK>; <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>) in which only <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK> described that outcome were also assessed blindly. Eleven studies reported the number and the reasons for patients leaving the trials (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>).</P>
<P>None of the studies reported effects from intention-to-treat (ITT) analysis; data was presented on a per-protocol basis in all trials.<BR/>
<BR/>Overall, 1736 patients were enrolled in the 15 studies that were included in the meta-analysis that evaluated the effectiveness of systemic antibiotic prophylaxis, and 398 patients in the two studies that were included in the meta-analysis that evaluated the use of antibiotic-impregnated catheters for surgical introduction of ventricular drains.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-01 21:18:40 +0200" MODIFIED_BY="Karen Hovhannisyan">
<P>We performed two separate meta-analyses given the clinical heterogeneity resulting from two interventions that were fundamentally different.</P>
<P>The first meta-analysis (15 RCTs) compared systemic prophylactic antibiotics with no antibiotic or placebo in patients with surgical introduction of ventricular drains.</P>
<P>The second meta-analysis (two RCTs) compared the use of antibiotic-impregnated shunt systems with standard shunt systems.</P>
<P>Missing data precluded the conduct of some planned analysis in this systematic review. We contacted the authors of the trials whenever we found this necessary, although no additional information was obtainable.</P>
<P>We tested heterogeneity between trials results using an I<SUP>2</SUP> test. Assuming that significant statistic heterogeneity is absent if I<SUP>2</SUP> is less than 50%, we found no evidence of heterogeneity for all groups in the measured outcomes. Therefore we used<BR/>fixed-effect models to synthesize data.</P>
<OL>
<LI>
<B>All cause mortality</B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>We could not analyse this outcome since there was only one trial (<LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>) that reported this outcome and there were no events.</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>We could access relevant data from two trials (<LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK>; <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK>) enrolling 398 patients. We found no significant differences (OR: 1.47, 95% CI 0.83 to 2.62). (See 'Comparisons and data' table 01/01)</LI>
</OL>
<LI>
<B>Shunt infection</B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis . </B>
</I>Analysis of the 15 included trials found a statistical significant difference for shunt infection that favoured treatment (OR: 0.52, 95% CI 0.36 to 0.74; NNT 12, 95% CI 7 to 30). Individually only one trial was statistically significant (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>). Two trials favoured the control group, although not statistically significant (<LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>). (See 'Comparisons and data' table 02/01)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>We found a statistical significant difference for shunt infection that favoured the use of antibiotic-impregnated catheters (OR: 0.21, 95% CI 0.08 to 0.55; NNT 4, 95% CI 2 to 14). (See 'Comparisons and data' table 01/02)</LI>
</OL>
<LI>
<B>Shunt revision</B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>We could access relevant data for this outcome from three trials (<LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>) involving 248 patients. We found there was no significant difference in shunt revision (OR: 0.76, 95% CI 0.42 to 1.36). (See 'Comparisons and data' table 02/02)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>G<LINK REF="STD-Govender-2003" TYPE="STUDY">ovender 2003</LINK> was the only eligible trial that used antibiotic-impregnated catheters for internal ventricular shunts (9/50 occurrences versus 15/60 controls). We found no significant difference between the groups (OR: 0.66, 95% CI 0.26 to 1.67). (See 'Comparisons and data' table 01/03)</LI>
</OL>
<LI>
<B>Adverse events of antibiotics. </B>Only two trials (<LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>) enrolling 163 patients reported the incidence of the adverse events of systemic antibiotics (8%, 7/87 occurrences). The eventual adverse effects of antibiotics from impregnated shunts were not reported in the eligible trials. (See 'Comparisons and data' table 02/03)</LI>
</OL>
<P>We were not able to study other proposed outcome measures such as disability, cognitive function, quality of life or length of hospital stay as no data were available.</P>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>Data on mortality was too sparse to perform subgroup analyses. We found that it was appropriate to perform subgroup analyses for the most frequent outcome: shunt infection. Regarding systemic antibiotics we performed subgroup analyses according to the type of shunt (internal versus external, ventriculoperitoneal versus ventriculoatrial), age (children versus all ages), and length of the administration of prophylactic systemic antibiotics (periprocedural: started immediately before placement of the drain and continued for three or fewer doses, or continued for less than 24 hours versus continuous antibiotics for the duration of drain placement or longer than 24 hours) and to perform subgroup analysis for antibiotic-impregnated systems according to the type of shunt (internal versus external).</P>
<OL>
<LI>
<B>1. Internal ventricular shunts versus external ventricular shunts</B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>We could include all eligible trials in this subgroup analysis showing a statistical significant difference for internal shunt infection that favoured treatment (OR: 0.52, 95% CI 0.36 to 0.74). Only one trial (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>) included a subgroup of patients with external shunts which was not statistically significant (OR: 1.08, 95% CI 0.06 to 18.30), with a weight of 1.05% in the total results. However no difference was found between the two subgroups (systemic antibiotics for internal versus external shunts; P = 0.2). (See 'Comparisons and data' table 02/01)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>The <LINK REF="STD-Govender-2003" TYPE="STUDY">Govender 2003</LINK> trial was the only RCT that evaluated infection of internal shunts and showed a non-significant difference between trial groups (OR: 0.32, 95% CI 0.08 to 1.23). <LINK REF="STD-Zabramski-2003" TYPE="STUDY">Zabramski 2003</LINK> evaluated external shunts and found a significant difference for this outcome (OR: 0.13, 95% CI 0.03 to 0.60). No difference was found between the two subgroups (antibiotic-impregnated devices for internal versus external shunts; P = 0.3). (See 'Comparisons and data' table 01/02)</LI>
</OL>
<LI>
<B>Ventriculoperitoneal (VP) shunts versus ventriculoatrial (VA) shunts</B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>We were able to include 13 trials in this subgroup analysis that enrolled 1416 patients. Although the <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK> trial did not detail the data, we included it in the subgroup analysis as a trial that enrolled only ventriculoperitoneal shunts (4 ventriculoatrial shunts out of 56 ventriculoperitoneal shunts). We excluded the <LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK> trial from this subgroup analysis because we could not discriminate the number of internal shunt type or the number of infections in each group. The author was contacted but could not provide additional information. Subgroup analyses for the effect of prophylactic systemic antibiotics of different type of internal shunts found a significant difference between treatment and control groups for both ventriculoatrial shunts (OR: 0.46, 95% CI 0.23 to 0.94) and ventriculoperitoneal shunts (OR: 0.54, 95% CI 0.34 to 0.85). No difference was found between the two subgroups (systemic antibiotics for ventriculoperitoneal versus ventriculoatrial shunts; P = 0.2). (See 'Comparisons and data' table 03/01)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>We did not find any relevant data on antibiotic-impregnated catheters.</LI>
</OL>
<LI>
<B>Children (under 18 years) versus all ages </B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>Subgroup analyses regarding the effect of prophylactic systemic antibiotics for internal shunts found a significant difference between treatment and control groups for both the subgroup of trials that included only children (OR: 0.52, 95% CI 0.33 to 0.83) and the subgroup of trials that included patients of all ages (OR: 0.52, 95% CI 0.30 to 0.90). No difference was found between the two subgroups (systemic antibiotics for children versus all ages; P = 0.06). (See 'Comparisons and data' table 04/01)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>We did not find any relevant data on antibiotic-impregnated catheters.</LI>
</OL>
<LI>
<B>Periprocedural systemic antibiotics (fewer than 4 doses or for less than 24 hours postoperatively) versus continuous systemic antibiotics </B>
</LI>
<OL>
<LI>
<I>
<B>Systemic antibiotic prophylaxis. </B>
</I>We were able to include the 15 trials that used systemic prophylactic antibiotics for the subgroup analysis of prophylactic periprocedural systemic antibiotics versus continuous systemic antibiotics and found a significant difference (OR: 0.53, 95% CI 0.34 to 0.83; OR: 0.50, 95% CI 0.36 to 0.74 respectively). No benefit was found for the use of continuous antibiotics compared with periprocedural administration (P = 0.1). (See 'Comparisons and data' table 05/01)</LI>
<LI>
<I>
<B>Antibiotic-impregnated catheters. </B>
</I>Not applicable.</LI>
</OL>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>As planned in the protocol, we performed a sensitivity analysis for well allocated, versus poorly or unclearly allocated trials regarding the use of systemic antibiotics. We lacked data on mortality and so were unable to perform a sensitivity analyses on this outcome. We therefore performed these analyses for shunt infection which was the most frequently reported outcome.<BR/>
<BR/>Class A trials: (<LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Schmidt-1985" TYPE="STUDY">Schmidt 1985</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>; <LINK REF="STD-Young-1987" TYPE="STUDY">Young 1987</LINK>; <LINK REF="STD-Zentner-1995" TYPE="STUDY">Zentner 1995</LINK>) enrolled 736 patients (362 in the treatment group and 374 in the control group) and showed a non statistical significant effect for shunt infection regarding the use of systemic antibiotics (OR: 0.78, 95% CI 0.44 to 1.38). Class B and C trials: (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Blum-1989" TYPE="STUDY">Blum 1989</LINK>; <LINK REF="STD-Djindjian-1986" TYPE="STUDY">Djindjian 1986</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Yogev-1985" TYPE="STUDY">Yogev 1985</LINK>) enrolled 1000 patients (505 in the treatment group and 495 in the control group), found a statistical significant difference for shunt infection and for the other studied endpoints that favoured treatment group (OR: 0.41, 95% CI 0.26 to 0.65). (See 'Comparisons and data' table 02/04)</P>
<P>We also performed a separate analysis for placebo controlled trials versus standard care controlled trials for the most frequent outcome: shunt infection, regarding the use of systemic antibiotics in internal shunts, that showed a statistical significance only for placebo controlled trials (OR: 0.46, 95% CI 0.30 to 0.71; OR: 0.66, 95% CI 0.34 to 1.26 respectively). (See 'Comparisons and data' table 02/05)</P>
<P>Funnel plots for shunt infection regarding the use of systemic antibiotics did not suggest selective reporting of trials (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-01 21:20:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<SUBSECTION>
<HEADING LEVEL="2">Quality of evidence</HEADING>
<P>We included 17 RCTs that met our inclusion criteria that evaluated the use of prophylactic antibiotics in patients with surgical introduction of ventricular shunts. We have described above, the methodological shortcomings of these studies . For instance none of the included trials used an intention-to-treat analysis (ITT) and about half of the trials either did not describe the randomization method or it was inadequately described. Only seven of the studies were double-blinded using identical appearance interventions (<LINK REF="STD-Blomstedt-1985" TYPE="STUDY">Blomstedt 1985</LINK>; <LINK REF="STD-Bullock-1988" TYPE="STUDY">Bullock 1988</LINK>; <LINK REF="STD-Haines-1982" TYPE="STUDY">Haines 1982</LINK>; <LINK REF="STD-Odio-1984" TYPE="STUDY">Odio 1984</LINK>; <LINK REF="STD-Rieder-1987" TYPE="STUDY">Rieder 1987</LINK>; <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK>; <LINK REF="STD-Wang-1984" TYPE="STUDY">Wang 1984</LINK>). The attrition rate was about 5%. We were able to study a total of 2134 patients integrated in two meta-analyses .</P>
<SUBSECTION>
<HEADING LEVEL="3">Systemic prophylactic antibiotics </HEADING>
<P>We included 15 RCTs, that met our inclusion criteria, that supported the use of systemic prophylactic antibiotics for primary prevention of shunt infection. We were able to study a total of 1736 patients. Only one trial stated data relative to all-cause mortality. Shunt infection was a primary outcome in all trials included. Only three trials evaluated shunt revision and two trials studied the adverse events of antibiotics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic-impregnated catheters </HEADING>
<P>Two trials compared antibiotic-impregnated catheters with standard ones for primary prevention of shunt infections; one trial for external ventricular drains/shunts, and one for internal (ventriculoperitoneal) shunts. The difference in these two clinical situations is reflected in the duration of follow-up: one week versus nine months, for the external<SUB> </SUB>versus the internal shunts respectively.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Methodology</HEADING>
<P>We considered it appropriate to perform two meta-analyses: one comparing systemic prophylactic antibiotic with placebo or no antibiotics and the second comparing antibiotic-impregnated catheters with standard ones. Although we intended to test other endpoints beside shunt infection, such as all-cause mortality, shunt revision, and adverse events of antibiotic, we were able only to include few trials in each one. We performed subgroup analyses for shunt infection whenever appropriate and where sufficient data was available.</P>
<P>We performed a sensitivity analyses that showed no significant differences for all endpoints when trials with poor or unclear allocation concealment were excluded. We combined trials that included different types of patients and with different follow-up periods.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Findings</HEADING>
<P>Only one trial evaluated the effect of systemic antibiotics in patients with external ventricular drains and included a small number of patients. No significant differences were found and no conclusions can be made for this particular type of ventricular shunt.</P>
<P>Based on subgroup analyses the benefit of systemic antibiotic prophylaxis was similar for children compared to a subgroup of patients constituted by patients of all ages, for ventriculoperitoneal shunts versus ventriculoatrial shunts and for periprocedural intravenous (IV) antibiotic therapy (given for less than 24 hours postoperatively), and continuous IV antibiotic therapy. Accordingly, administration of prophylactic antibiotics for more than 24 hours postoperatively does not have support. It would be desirable to have a head-to-head comparison of these two strategies. It should be emphasized that the lack of evidence of difference between the groups is consistent with there either being no difference between these groups in terms of effect size, or that there are too few people in the studies to allow a clear conclusion to be made due to lack of power.</P>
<P>The validity of the review may be weakened by the fact that when we performed the sensitivity analysis for adequate allocated trials regarding the use of systemic antibiotics that included seven RCTs, we found a non-significant effect for shunt infection (OR: 0.78, 95% CI 0.44 to 1.38), as it occured with the remaining endpoints studied. However it is worth noticing the two subgroups maintain the same trend. The group of A trials is smaller which may account for the loss of statistical significance. In addition, all studies presented the data on a per-protocol basis which may also inflate the effect size. This aspect may be particularly important in <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK> and <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK>. These two studies reported a high dropout rate (24/78 = 31% and 51/294 = 17% respectively) although the <LINK REF="STD-Rocca-1992" TYPE="STUDY">Rocca 1992</LINK> study had less weight (0.49%) and the <LINK REF="STD-Walters-1992" TYPE="STUDY">Walters 1992</LINK> study is important but below the critical 20% level. Overall we believe that systemic antibiotics do have a beneficial effect but it is possible that the effect size is smaller than the one estimated in our review.<BR/>
<BR/>We found two RCTs that compared the antibiotic-impregnated shunts with the standard catheters.</P>
<P>Given the current data, it is possible to recommend the use of periprocedural systemic prophylactic antibiotic in patients undergoing surgical introduction of internal ventricular shunts; even though it was not possible to clearly evaluate the incidence of adverse effects of the antibiotics. The use of antibiotic-impregnated catheters in ventricular shunts seems to be advantageous. This evidence is only limited by the low number of studies and participants; further well conducted RCTs are required to clarify this issue. However, our results suggest that the AIS are effective across populations: heterogeneity of populations across studies can make results more generalizable. The trials tested widely different antibiotics which have varied safety profiles. The impact of the actual antibiotics chosen could not be evaluated.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This systematic review shows a significant difference between systemic prophylactic antibiotics and control for the prevention of shunt infection in patients with surgical introduction of internal ventricular shunts; regardless of the patient's age and the type of internal shunt used. Therefore its use in current practice is recommended even if there is sparse mortality data. Shunt infection was an intermediate outcome in this review and the type and dose of antibiotic needs to be optimized. Currently the available evidence only suggests a benefit for the use of prophylactic antibiotics for the first 24 hours postoperatively. The benefit of its use after the first 24 hours postoperatively remains uncertain. </P>
<P>No conclusions can be reached regarding the administration of prophylactic antibiotics for external ventricular drains. The evidence suggests that antibiotic-impregnated catheters reduce the incidence of shunt infection although no strong recommendation can be made given the current data available. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future RCTs should study relevant outcomes such as mortality, antibiotics' adverse events and shunt revision. It should also be mandatory to evaluate the effectiveness of systemic prophylactic antibiotics for external ventricular drains, and the effectiveness of different regimens of systemic prophylactic antibiotics rather than placebo for internal ventricular shunts; namely the duration of the administration. More appropriately designed randomized controlled trials which test the effect of antibiotic-impregnated shunts are required in order to establish whether or not there is a net benefit of this medication. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Dr Harald Herkner, Jane Cracknell, Dr Andrea Nelson, Dr Jeffrey J. Olson, Dr Thomas Sycha, Dr Joseph M. Zabramski, Prof. Marcus Müllner, Janet Wale and Nete Villebro for their help and editorial advice during the preparation of this review and to Karen Hovhannisyan for conducting some of the electronic searches. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All correspondence: Bernardo Ratilal (BORL).</P>
<P>Drafting of review versions: BORL, Joao Costa (JOAC) and Cristina Sampaio (SCRI).</P>
<P>Searching for trials: BORL and JOAC.</P>
<P>Obtaining copies of trial reports: BORL and JOAC.</P>
<P>Selection of trials for inclusion and exclusion: BORL, JOAC and SCRI.</P>
<P>Extraction of data: BORL and JOAC.</P>
<P>Entry of data (in Review Manager (RevMan 4.2)): BORL and JOAC.</P>
<P>Interpretation of data analyses: BORL, JOAC and SCRI.</P>
<P/>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayston-1975" NAME="Bayston 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bayston R</AU>
<TI>Antibiotic prophylaxis in shunt surgery</TI>
<SO>Developmental Medicine and Child Neurology Supplement</SO>
<YR>1975</YR>
<VL>35</VL>
<PG>99-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1060602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blomstedt-1985" NAME="Blomstedt 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blomstedt GC</AU>
<TI>Results of trimethoprim-sulfamethoxazole prophylaxis in ventriculostomy and shunting procedures. A double-blind randomized trial</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1985</YR>
<VL>62</VL>
<NO>5</NO>
<PG>694-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3886851"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-1989" NAME="Blum 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blum J, Schwarz M, Voth D</AU>
<TI>Antibiotic single-dose prophylaxis of shunt infections</TI>
<SO>Neurosurgical Review</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>3</NO>
<PG>239-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2510054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bullock-1988" NAME="Bullock 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bullock R, van Dellen JR, Ketelbey W, Reinach SG</AU>
<TI>A double-blind placebo-controlled trial of perioperative prophylactic antibiotics for elective neurosurgery</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1988</YR>
<VL>69</VL>
<NO>5</NO>
<PG>687-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3054011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Djindjian-1986" NAME="Djindjian 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Djindjian M, Fevrier MJ, Otterbein G, Soussy JC</AU>
<TI>Oxacillin prophylaxis in cerebrospinal fluid shunt procedures: results of a randomized open study in 60 hydrocephalic patients</TI>
<SO>Surgical Neurology</SO>
<YR>1986</YR>
<VL>25</VL>
<NO>2</NO>
<PG>178-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3510475"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Govender-2003" NAME="Govender 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Govender ST, Nathoo N, van Dellen JR</AU>
<TI>Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2003</YR>
<VL>99</VL>
<NO>5</NO>
<PG>831-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14609161"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nathoo N, Govender ST, Barnett GH, van Dellen JR</AU>
<SO>Evaluation of an antimicrobial impregnated shunt system for the treatment of hydrocephalus. Presented at the American Association of Neurological Surgeons 2004 Annual Meeting</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="19604 (www.aans.org)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haines-1982" NAME="Haines 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haines SJ, Taylor F</AU>
<TI>Prophylactic methicillin for shunt operations: effects on incidence of shunt malfunction and infection</TI>
<SO>Child's Brain</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>1</NO>
<PG>10-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7037325"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odio-1984" NAME="Odio 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Odio C, Mohs E, Sklar FH, Nelson JD, McCracken GH</AU>
<TI>Adverse reactions to vancomycin used as prophylaxis for CSF shunts procedures</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1984</YR>
<VL>138</VL>
<NO>1</NO>
<PG>17-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6229176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rieder-1987" NAME="Rieder 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rieder MJ, Frewen TC, Del Maestro RF, Coyle A, Lovell S</AU>
<TI>The effect of cephalothin prophylaxis on postoperative ventriculoperitoneal shunt infections</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1987</YR>
<VL>36</VL>
<NO>9</NO>
<PG>935-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3552176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocca-1992" NAME="Rocca 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rocca B, Mallet MN, Scemama F, Malca S, Chevalier A, Gouin F</AU>
<TI>Perioperative remote infections in neurosurgery. Role of antibiotic prophylaxis</TI>
<TO>Infections à distance du foyer opératoire en neurochirurgie. Rôle de l'antibioprophylaxie</TO>
<SO>La Presse Médicale</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>42</NO>
<PG>2037-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1294976"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1985" NAME="Schmidt 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt K, Gjerris F, Osgaard O, Hvidberg EF, Kristiansen JE, Dahlerup B, et al</AU>
<TI>Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 152 hydrocephalic patients</TI>
<SO>Neurosurgery</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3895024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walters-1992" NAME="Walters 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walters BC, Goumnerova L, Hoffman HJ, Hendrick EB, Humphreys RP, Levinton C</AU>
<TI>A randomized controlled trial of perioperative rifampin/trimethoprim in cerebrospinal fluid shunt surgery</TI>
<SO>Child's Nervous System</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>5</NO>
<PG>253-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1296606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1984" NAME="Wang 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang EE, Prober CG, Hendrick BE, Hoffman HJ, Humphreys RP</AU>
<TI>Prophylactic sulfamethoxazole and trimethoprim in ventriculoperitoneal shunt surgery. A double-blind, randomized, placebo-controlled trial</TI>
<SO>JAMA</SO>
<YR>1984</YR>
<VL>251</VL>
<NO>9</NO>
<PG>1174-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6363740"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yogev-1985" NAME="Yogev 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yogev R</AU>
<TI>Cerebrospinal fluid shunt infections: a personal view</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>113-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3885175"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1987" NAME="Young 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young RF, Lawner PM</AU>
<TI>Perioperative antibiotic prophylaxis for prevention of postoperative neurosurgical infections. A randomized clinical trial</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1987</YR>
<VL>66</VL>
<NO>5</NO>
<PG>701-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3553455"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zabramski-2003" NAME="Zabramski 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, et al</AU>
<TI>Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>4</NO>
<PG>725-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12691395"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zentner-1995" NAME="Zentner 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zentner J, Gilsbach J, Felder T</AU>
<TI>Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 129 patients</TI>
<SO>Neurosurgical Review</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3</NO>
<PG>169-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8570063"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1982" NAME="Epstein 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Epstein MH, Kumor K, Hughes W, Lietman P</AU>
<TI>Use of prophylactic antibiotics in pediatric shunting operations - a double-blind prospective study</TI>
<SO>Presented at the American Association of Neurological Surgeons Annual Meeting</SO>
<YR>1982</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1986" NAME="Shapiro 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro M, Wald U, Simchen E, Pomeranz S, Zagzag D, Michowiz SD, et al</AU>
<TI>Randomized clinical trial of intra-operative antimicrobial prophylaxis of infection after neurosurgical procedures</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>3</NO>
<PG>283-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2878034"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siqueira-1987" NAME="Siqueira 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siqueira MG, Koury LS, Silva AD, Jabur A, Rezende Filho CP</AU>
<TI>Intraoperative antibiotic prophylaxis in neurosurgery: a randomized controlled clinical trial</TI>
<TO>Profilaxia antibiótica transoperatória em neurocirurgia: estudo prospectivo controlado</TO>
<SO>Arquivos Brasileiros de Neurocirurgia</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>5-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-Alleyne-2000" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Alleyne 2000" TYPE="JOURNAL_ARTICLE">
<AU>Alleyne CH, Hassan M, Zabramski JM</AU>
<TI>The efficacy and cost of prophylactic and perioprocedural antibiotics in patients with external ventricular drains</TI>
<SO>Neurosurgery</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>1124-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11063105"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11860606"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bondurant-1995" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Bondurant 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bondurant CP, Jimenez DF</AU>
<TI>Epidemiology of cerebrospinal fluid shunting</TI>
<SO>Pediatric Neurosurgery</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>254-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8688350"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borges-1982" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Borges 1982" TYPE="JOURNAL_ARTICLE">
<AU>Borges LF</AU>
<TI>Cerebrospinal fluid shunts interfere with hosts defenses</TI>
<SO>Neurosurgery</SO>
<YR>1982</YR>
<VL>10</VL>
<PG>55-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7057979"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Claus-2004" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Claus 2004" TYPE="BOOK_SECTION">
<AU>Claus BC</AU>
<TI>Shunt Infection</TI>
<SO>Youmans Neurological Surgery</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>3419-25</PG>
<EN>5th Ed</EN>
<ED>H. Richard Winn</ED>
<PB>Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-09-01 21:06:46 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin 1994. Dickersin K, Scherer R, Lefebvre C.  Identifying relevant studies for systematic reviews.  BMJ 1994; 309:1286-91.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-01 21:06:46 +0200" NOTES_MODIFIED_BY="Karen Hovhannisyan" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1993" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Fleiss 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JL Fleiss JL.</AU>
<TI>The statistical basis of meta-analysis.</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>1993</YR>
<VL>2</VL>
<NO>2</NO>
<PG>121-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8261254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frazee-1988" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Frazee 1988" TYPE="JOURNAL_ARTICLE">
<AU>Frazee RC, Mucha P Jr, Farnell MB, Ebersold MJ</AU>
<TI>Meningitis after basilar skull fracture. Does antibiotic prophylaxis help?</TI>
<SO>Postgraduate Medicine</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>5</NO>
<PG>267-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3357863"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haines-1994" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Haines 1994" TYPE="JOURNAL_ARTICLE">
<AU>Haines SJ, Walters BC</AU>
<TI>Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis</TI>
<SO>Neurosurgery</SO>
<YR>1994</YR>
<VL>34</VL>
<PG>87-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8121573"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Intervention 4.2.5 [updated in May 2005]</TI>
<SO>The Cochrane Library, Issue 3, 2005</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langley-1993" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Langley 1993" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, LeBlanc JC, Drake J, Milner R</AU>
<TI>Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis</TI>
<SO>Clinical infectious Diseases</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>98-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8353253"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moss-1991" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Moss 1991" TYPE="JOURNAL_ARTICLE">
<AU>Moss AJ, Hamburger S, Moore RM Jr, Jeng LL, Howie LJ</AU>
<TI>Use of selected medical device implants in the United States, 1988</TI>
<SO>Advance Data</SO>
<YR>1991</YR>
<VL>191</VL>
<NO>26</NO>
<PG>1-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10170709"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-4.2" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="RevMan 4.2" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) [Computer program]. Version 4.2 for Windows</TI>
<YR>2003</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smeeth-1999" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Smeeth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Smeeth L, Haines A, Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<NO>7197</NO>
<PG>1548-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10356018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stenager-1986" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NAME="Stenager 1986" TYPE="JOURNAL_ARTICLE">
<AU>Stenager E, Gerner-Smidt P, Kock-Jensen C</AU>
<TI>Ventriculostomy-related infections: an epidemiological study</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1986</YR>
<VL>83</VL>
<NO>1-2</NO>
<PG>20-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3799246"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bayston-1975">
<CHAR_METHODS>
<P>Randomized, controlled, not blinded.<BR/>Method of randomization: not specified.<BR/>Location: single centre in UK.<BR/>Duration: Not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: patients (children) undergoing shunt surgery.<BR/>Exclusion criteria: not specified.<BR/>Characteristics of each group were not described.<BR/>132 patients completed the trial (treatment group n = 34+20, control group n = 78). <BR/>Baseline for variables between groups were not performed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: 1st phase - control group (no AB) and AB group (cloxacillin IM 1 hour before operation and 6 hours after); 2nd phase - control group and AB group (gentamicin IM 1 hour before operation and 6 hours after).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events considered were wound infection and colonized shunts (organisms isolated from wounds and shunts).<BR/>Period of observation not specified<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blomstedt-1985">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: not specified.<BR/>Location: single centre in Finland.<BR/>Duration: 39 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: All patients (above 12 years) undergoing a ventriculoatriostomy or an external ventriculostomy <BR/>Exclusion criteria: patients under 12 years, allergy to sulfa or trimethoprim, patients who had received antibiotics during the preceding week, and patients who had already had a shunt in place.<BR/>174 patients were enrolled in the trial (62 in group 1, 60 in group 2, 25 in group 3 and 27 in group 4); 26 were excluded (19 regimen was not completed, 6 received other AB, 1 suspected allergic reaction).<BR/>Age, sex, incidence of malignant tumours were similar in the two treatment groups.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>For shunting procedures: Group 1 (trimethoprim 90 mg -sulphametoxazole 400 mg x 3 doses 12-hourly; Group 2 (placebo)<BR/>For external ventriculostomies: <BR/>Group 3 (trimethoprim 90mg -sulphametoxazole 400mg 12-hourly until drainage tube removal); Group 4 (placebo).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (bacteria isolated from cultures from blood, shunt catheter, or CSF whenever shunt infection was suspected). <BR/>Minimum follow-up period of 6 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Blum-1989">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, single blinded.<BR/>Method of randomization: date of birth<BR/>Location: single centre in Germany.<BR/>Duration: 21 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: All patients (children up to 14 years) operated on for hydrocephalus.<BR/>Exclusion criteria: hypersensitivity to the drug selected, antibiotic therapy in the previous 7 days or another antibiotic in the posterior 10 days, concurrent infections, immunosuppressive therapy or immunodeficiency, agammaglobulinemia, agranulocytosis, leukemia, severe anemia, lymphoma, thymus aplasia, liver cirrhosis, burns, uremia, diabetes mellitus and factors which impairs wound healing. <BR/>From 169 patients, 100 patients meet inclusion criteria (AB group n = 50, control group n = 50).<BR/>Age and sex were similar in the two treatment groups.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (single-dose prophylaxis with 50mg/kg body-weight of cefazedone) or placebo group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (diagnosis on microbiological and clinical observations and investigations, such as local signs of infection, pathogen detection, germ counts, and antibiograms. Classical infection parameters played only a secondary role.)<BR/>Follow-up period lasted 8 weeks.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted but no further data was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bullock-1988">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded<BR/>Method of randomization: random number list.<BR/>Location: single centre in South Africa.<BR/>Duration: 2 years.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>patients (regardless of age) undergoing elective neurosurgical procedure.<BR/>Exclusion criteria: known piperacillin hypersensitivity or allergy, neurosurgical operation in the previous month, any AB therapy within 7 days prior the study.<BR/>417 patients were enrolled in the trial in which 104 were ventriculoperitoneal shunts (treatment group n = 48, control group n = 56).<BR/>Treatment and placebo groups were well matched for age, sex, hospital stay, operation time and duration of vacuum drainage. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (piperacillin 2g IV commenced between 30 and 60 minutes prior to the surgical incision and two further doses 6- hourly) and placebo group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were sepsis (purulent discharge from a wound, meningitis verified by a low sugar and high polymorphonuclear lymphocyte count in the CSF or when pure culture of organisms from a wound exudate when redness was present).<BR/>Follow-up period of 90 days.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Djindjian-1986">
<CHAR_METHODS>
<P>Randomized, controlled, not blinded.<BR/>Method of randomization: Not specified. <BR/>Location: single centre in France<BR/>Duration: 27 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: patients (regardless of age) receiving first implantation of shunt.<BR/>Exclusion criteria: no AB in the previous 14 days, previous ventricular drainage, replacement of a previously implanted shunt.<BR/>Treatment group n = 30, control group n = 30. Baseline for variables between groups were not performed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (oxacillin 200mg /kg/day with an IV administration every 4 hours for 24 hours (6 x 2g for an adult) and control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was CSF infection (meningitis or abscess of the wall with meningeal reaction and CSF cell count was clearly suggestive of infection, even when bacteria could not be isolated form the CSF or the shunt system).<BR/>Minimum follow-up period of 6 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted but no further data provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Govender-2003">
<CHAR_METHODS>
<P>Randomized, controlled, single blind.<BR/>Method of randomization: not specified.<BR/>Location: 2 centre, South Africa and UK.<BR/>Duration: Not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Patients (regardless of age) with hydrocephalus who had been identified primarily as uninfected.<BR/>Exclusion criteria: CSF infection before or at the time of shunt insertion, pregnancy or lactancy, known sensitivity to rifampicin or clindamycin, or open and uncorrected myelomeningocele or encephalocele.<BR/>153 patients were enrolled, 43 were later excluded (19 deaths before appropriate follow-up period, 7 protocol violations, 2 CSF infection at the time of the shunt insertion, 15 did not return for follow-up); AIS group n = 50, control group n = 60. <BR/>No significant difference in the median follow-up period between groups.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: AIS group (patients receiving an AIS with clindamycin and rifampicin) or a control group (patients receiving a standard unishunt system that lacked any antibiotic agent).<BR/>All patients were given cephalosporin IV at induction of anaesthesia and 3 postoperative doses given 8-hourly. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were shunt infection (evidence of infection on shunt equipment, overlying wound, CSF, distal drainage route, or site related to the ventriculoperitoneal shunt) and shunt revision procedure (due to infection or non infectious causes).<BR/>Median follow-up period of 9 months (range 1-20 months).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Haines-1982">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: coin toss.<BR/>Location: single centre in USA.<BR/>Duration: 1 year.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Children ( under 17 years) for insertion or revision of CSF shunts.<BR/>Exclusion criteria: allergy to penicillin, patients who were on antibiotic therapy.<BR/>76 patients were enrolled on the trial. 2 were excluded due to CSF infection at the time of operation. Treatment group n = 35, placebo group n = 39.<BR/>The 2 groups were well matched for age, sex, previous shunt infection, presence of spina bifida, having first shunt placement, CSF glucose, protein or WBC values. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: antibiotic group (methicillin 12,5mg/kg every 6 hours beginning 6 hours before the operation, during the induction of anaesthesia, and continuing for a total of 72 hours) and placebo group (placebo in an identical regimen).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were shunt infection (required a positive CSF culture except when there was gross purulence along the shunt tract, organisms were seen on gram-stain of CSF smears or the CSF protein, glucose and cell count were felt to be indicative of infection) and shunt malfunction (clinical criteria and almost always confirmed by CT scan).<BR/>Follow-up period of 6 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Odio-1984">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: central computer-generated list of random numbers.<BR/>Location: 2 centres, Costa Rica and USA.<BR/>Duration: 5 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Children undergoing shunt procedures.<BR/>Exclusion criteria: laboratory evidence of hepatic or renal disease, antibiotics received in the previous 72 hours.<BR/>37 patients were enrolled in the study. 2 were excluded because of adverse reactions to AB in the first dose. Treatment group n = 18, placebo group n = 17.<BR/>Baseline for variables between treatment and placebo groups were not performed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (vancomycin 15mg/kg IV one hour before surgery and 6 hours later) and placebo group (placebo in an equivalent volume given at the same time.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were shunt infection (based on examination of CSF that included a Gram-stained smear, culture, cell count and protein and glucose determination whenever shunt infection was suspected on the basis of shunt malfunction, fever, nausea, or vomiting) and adverse effects of vancomycin.<BR/>Follow-up period of 7-12 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted but no further data provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rieder-1987">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: envelope draw system.<BR/>Location: single-centre in UK.<BR/>Duration: 4 years.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Children who presented for elective ventriculoperitoneal shunt insertion. <BR/>Exclusion criteria: evidence of active infection, history of shunt infection, immunosuppressed, corticosteroid therapy, allergies to penicillin or cephalothin, antibiotic therapy in the 4 weeks before shunt insertion.<BR/>Treatment group n = 31, placebo group n = 32.<BR/>The 2 groups were well matched for age, sex, history of CSF infection and duration of surgery. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomised to one of two groups: treatment group (cephalothin 25mg/kg or 2g maximum IV before incision and 3 doses 6-hourly) and placebo group (multivitamin preparation of the same colour and administered as the same regimen).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were shunt infection (if there were symptoms suggestive of shunt infection including irritability, reddening of the skin overlying the shunt tubing or unexplained fever and culture of CSF yielded bacterial growth) and shunt malfunction. <BR/>Follow-up period of 3 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rocca-1992">
<CHAR_METHODS>
<P>Randomized, controlled.<BR/>Method of randomization: not specified.<BR/>Location: single centre in France.<BR/>Duration: 2 years.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Patients (regardless of age) submitted to craniotomy or shunt placement.<BR/>Exclusion criteria: infection or antibiotherapy in the previous 15 days, allergy to B-lactams, urgent surgeries and reinterventions.<BR/>78 patients were enrolled in the study, in which 27 were shunt procedures (treatment group n = 13, control group n = 14).<BR/>Baseline for variables between treatment and control groups were not performed. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (cefamandole 1.5g IV was given 1 hour before surgery and 3 doses 8-hourly) and control group (no antibiotic).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event were local and remote infections (wound discharge, leucytosis and fever associated with appropriate positive germ culture).<BR/>Follow-up period for 15 days.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schmidt-1985">
<CHAR_METHODS>
<P>Randomized, controlled, not blinded.<BR/>Method of randomization: random numbers<BR/>Location: 2 centre in Denmark.<BR/>Duration: 18 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Patients (regardless of age) who presented for shunt insertion or shunt revision.<BR/>Exclusion criteria: no antibiotic had been given or signs of infection in the preceding 4 weeks.<BR/>152 patients were enrolled in the study, none were excluded (antibiotic group n = 79, control group n = 73) <BR/>The 2 groups were well matched for age, sex, etiology of hydrocephalus, observation time, method of shunt and duration of the operation. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: antibiotic group (methicillin totally 200mg/kg divided in 6 doses during 24 hours starting at the induction of anaesthesia) and control group (no antibiotic).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (when patient showed clinical signs of wound infection, septicaemia in patients with VA shunts, peritonitis in patients with VP shunts, or meningitis and if bacteria could be cultivated from blood, peritoneum, CSF, or the shunt system).<BR/>Follow-up period for at least 6 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Walters-1992">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: not specified.<BR/>Location: single centre in Canada.<BR/>Duration: 44 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Children undergoing CSF shunt procedure.<BR/>Exclusion criteria: shunt infection, concomitant systemic infection, allergies to rifampicin or trimethoprim.<BR/>294 patients were enrolled in which 51 were withdrawal (15 lost to follow-up and 36 infected at the time of initial surgery); Treatment group n = 130, placebo group n = 113.<BR/>Baseline for variables between treatment and placebo groups were not performed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (20mg/Kg rifampicin and 5mg/kg trimethoprim per day in divided doses, the first 2 hours preoperatively and 8-hourly for further 48 hours) and placebo group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (patients who required additional surgery for malfunction and were found at operation to have positive microbiological cultures from shunt tubing and/or CSF and those patients who presented with a reddened and oedematous shunt tract, pus from the wound, meningitis, or other systemic forms of infection and verified by positive cultures).<BR/>Follow-up period of 2 years.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1984">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blinded.<BR/>Method of randomization: table of random numbers.<BR/>Location: single centre in Canada.<BR/>Duration: 30 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>Children undergoing ventriculoperitoneal shunt surgery.<BR/>Exclusion criteria: shunt infection in the preceding month, antibiotic therapy within the previous week, allergy to trimethoprim or sulfamethoxazole.<BR/>127 patients were enrolled in the study. 7 withdrawals (unsuspected VP shunt infection diagnosed at the time of surgery); Treatment group n = 55, placebo group n = 65. The 2 groups were well matched for age, sex, history of shunt infection and duration of the operation. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (5mg/kg in combination with 25mg/kg of sulfamethoxazole IV during the hour preceding the surgery and 2 more doses 8-hourly) and placebo group (equivalent volumes of 5%dextrose in water administered in an identical fashion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome events were shunt infection (when bacteria were recovered from CSF or VP catheter specimens) or shunt malfunction. Duration of follow-up was from the time of shunt surgery until the last patient contact.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yogev-1985">
<CHAR_METHODS>
<P>Randomized, placebo-controlled.<BR/>Method of randomization: not specified.<BR/>Location: single centre in USA.<BR/>Duration: not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria: all patients (children) undergoing ventriculoperitoneal shunt replacement or revision.<BR/>Exclusion criteria: not specified.<BR/>190 patients were enrolled in the trial, treatment group n = 106 and placebo group n = 84).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (nafcillin alone or nafcillin and rifampicin 200mg/kg per day and 20mg/kg per day started 13 hours preoperatively and continued for 48 hours) and placebo group (saline placebo).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (shunt infection criteria was not described).<BR/>Follow-up period for 6 months.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Young-1987">
<CHAR_METHODS>
<P>Randomized, controlled, single blinded.<BR/>Method of randomization: table random of numbers.<BR/>Location: multicentre (3 centres), USA<BR/>Duration: 56 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>clean neurosurgical procedure (regardless age)<BR/>Exclusion criteria: evidence of any concurrent infection, use of AB for any reason in the prior week, history of allergic reactions to cephalosporin or aminoglycosides. 846 patients were enrolled in the study, 16 were excluded <BR/>(8 in each group and none had infection); reasons: 4 used AB in the prior week, 2 had inadvertent administration of AB following surgery, 4 had unsuspected brain abscess, 1 preoperative infection and 5 had inability to verify that the protocol was administered according to protocol. 133 patients underwent shunt placement (64 in the treatment group and 69 in the control group).<BR/>The 2 groups were well matched for sex, and duration of the procedure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (cefazolin 1g and gentamicin 80mg or 1mg/kg and 25mg/kg in paediatric patients respectively, IV, 1 hour before the incision and repeated every 6 hours as long as the operation procedure continued) and a control group (no AB).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was postoperative infection (wound infection, meningitis or ventriculitis confirmed with appropriate cultures). Minimum follow-up period of 1 year.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted but no further data was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zabramski-2003">
<CHAR_METHODS>
<P>Randomized, controlled.<BR/>Method of randomization: central automated system.<BR/>Location: multicentre (6 centres) in USA.<BR/>Duration: 27 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>All hospitalized patients (18 years or older) who required placement of external ventricular drain. Exclusion criteria: pregnancy, allergies to tetracycline or rifampicin, dermatitis or infection at the catheter insertion site, CSF shunt within the previous 30 days, known or suspected CSF infection, need for placement of more than one ventricular catheter, and uncorrected coagulopathy.<BR/>306 patients were enrolled in the study, in which 288 were included in the final analysis (14 excluded because ventricular catheter remained in place for less than 24 hours, 4 because of initial CSF culture revealed infection). Treatment group n = 149, control group n = 139. <BR/>The 2 groups were well matched for age, sex, indication for catheter placement and length of time the catheter remained in place. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (catheter impregnated with minocycline and rifampicin) and control group (standard non-impregnated silicone catheter).<BR/>Most patients received a second-generation cephalosporin begun before the catheter is placed and continued until the catheter is removed.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was CSF infection (positive CSF culture if the same organism grew on two different media or grew in the same medium twice).<BR/>Follow-up period of 1 week after catheter removal.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zentner-1995">
<CHAR_METHODS>
<P>Randomized, controlled.<BR/>Method of randomization: computerized lists.<BR/>Location: single centre in Germany.<BR/>Duration: 1 year.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria:<BR/>All patients (regardless of age) undergoing CSF shunting.<BR/>Exclusion criteria: Not specified.<BR/>Treatment group n = 67, control group n = 62.<BR/>The 2 groups were well matched for age, etiology of hydrocephalus, shunting procedure, shunt type, risk factors, duration of operation, and duration of preoperative hospitalization.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomized to one of two groups: treatment group (cefotiam IV in a single dose 50mg/kg for children and 2g for adults after induction of anaesthesia and before the skin incision) and control group (no antibiotics).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome event was shunt infection (presence of clinical symptoms, elevated cell counts, and/or bacterial contamination of CSF requiring shunt removal and AB therapy).<BR/>Follow-up period of 6 months after surgery.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author contacted but no further data was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AB = antibiotic<BR/>IM = intramuscularly<BR/>mg = milligram<BR/>g = gram<BR/>IV = intravenously<BR/>CSF = cerebrospinal fluid<BR/>AIS = antibiotic-impregnated system<BR/>WBC = white blood cell<BR/>kg = kilogram<BR/>CT = computerized tomography<BR/>VA = ventriculoatrial<BR/>VP = ventriculoperitoneal<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Epstein-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial comparing the use of both systemic and intraventricular cephalothin for 72 hours with placebo. 77 patients were enrolled in the trial. There were 1/39 shunt infections in the treatment group and 8/38 shunt infections in the control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shapiro-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled double-blinded trial comparing the use of periprocedural systemic vancomycin and gentamycin with placebo in all patients undergoing neurosurgery. There was one case of infection in patients undergoing ventricular shunts but it was not specified in which group it occurred. Further data was unavailable from the author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siqueira-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial comparing intra-operative systemic antibiotics as a factor in reducing the incidence of wound infection in clean procedures. Author divided patients in four groups: cranial surgery with implants (71 patients); cranial surgery without implants (54 patients); spinal surgery (54 patients); and peripheral nerve surgery (23 patients). The study mentioned that the subgroup of patients submitted to CSF shunting was included in the cranial surgery with implants group but details on the number of patients, and the number of infections in this subgroup were not given. Further data were unavailable from the author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bayston-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blomstedt-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Blum-1989">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bullock-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Djindjian-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Govender-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Haines-1982">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Odio-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rieder-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rocca-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schmidt-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Walters-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wang-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yogev-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Young-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Zabramski-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Zentner-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-01 21:06:01 +0200" MODIFIED_BY="Karen Hovhannisyan"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Antibiotic-impregnated versus standard catheters</NAME>
<DICH_OUTCOME CHI2="0.27045293624709754" CI_END="2.6178865026592972" CI_START="0.8259243098050351" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4704339845286483" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4179508139728488" LOG_CI_START="-0.08305975091230355" LOG_EFFECT_SIZE="0.16744553153027258" METHOD="MH" NO="1" P_CHI2="0.6030281521185801" P_Q="0.0" P_Z="0.19016168352458027" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="199" WEIGHT="100.00000000000001" Z="1.3101009606323626">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.308913687998801" CI_START="0.4787658660110422" DF="0.0" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.9688990035555608" LOG_CI_START="-0.31987682052855254" LOG_EFFECT_SIZE="0.3245110915135041" NO="1" P_CHI2="1.0" P_Z="0.3236280580305493" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="12.744198243083781" Z="0.9870297689704933">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="9.308913687998801" CI_START="0.4787658660110422" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9688990035555608" LOG_CI_START="-0.31987682052855254" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="1" O_E="0.0" SE="0.7570332986102253" STUDY_ID="STD-Govender-2003" TOTAL_1="50" TOTAL_2="60" VAR="0.5730994152046784" WEIGHT="12.744198243083781"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.577806566404481" CI_START="0.7354089786354416" DF="0.0" EFFECT_SIZE="1.3768595041322313" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.41125032562602026" LOG_CI_START="-0.1334710721173829" LOG_EFFECT_SIZE="0.13888962675431868" NO="2" P_CHI2="1.0" P_Z="0.3175629562972173" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="139" WEIGHT="87.25580175691623" Z="0.9994785128411894">
<NAME>External shunts</NAME>
<DICH_DATA CI_END="2.5778065664044814" CI_START="0.7354089786354414" EFFECT_SIZE="1.3768595041322313" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.4112503256260204" LOG_CI_START="-0.13347107211738304" LOG_EFFECT_SIZE="0.13888962675431868" ORDER="2" O_E="0.0" SE="0.3199720454488812" STUDY_ID="STD-Zabramski-2003" TOTAL_1="149" TOTAL_2="139" VAR="0.10238210986874088" WEIGHT="87.25580175691623"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7414428748492975" CI_END="0.5533471610403258" CI_START="0.07611455308827378" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.20522614810313397" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.2570023138691077" LOG_CI_START="-1.1185322982666035" LOG_EFFECT_SIZE="-0.6877673060678555" METHOD="MH" NO="2" P_CHI2="0.38919909567828836" P_Q="0.0" P_Z="0.0017521464495370345" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="199" WEIGHT="100.0" Z="3.1293145312402473">
<NAME>Shunt infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.231409928871937" CI_START="0.08271497660562663" DF="0.0" EFFECT_SIZE="0.3191489361702128" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.0904026509908126" LOG_CI_START="-1.0824158487508848" LOG_EFFECT_SIZE="-0.4960065988800362" NO="1" P_CHI2="1.0" P_Z="0.09735583900717504" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="39.17006684608039" Z="1.6578099170727343">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="1.2314099288719365" CI_START="0.08271497660562663" EFFECT_SIZE="0.3191489361702128" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.09040265099081245" LOG_CI_START="-1.0824158487508848" LOG_EFFECT_SIZE="-0.4960065988800362" ORDER="3" O_E="0.0" SE="0.6889193922934773" STUDY_ID="STD-Govender-2003" TOTAL_1="50" TOTAL_2="60" VAR="0.47460992907801414" WEIGHT="39.17006684608039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5954983686822767" CI_START="0.02920109460731182" DF="0.0" EFFECT_SIZE="0.13186813186813187" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.22511942389280043" LOG_CI_START="-1.534600868654137" LOG_EFFECT_SIZE="-0.8798601462734688" NO="2" P_CHI2="1.0" P_Z="0.00844207448335556" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="139" WEIGHT="60.82993315391961" Z="2.633858165806153">
<NAME>External shunts</NAME>
<DICH_DATA CI_END="0.5954983686822767" CI_START="0.02920109460731182" EFFECT_SIZE="0.13186813186813187" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22511942389280043" LOG_CI_START="-1.534600868654137" LOG_EFFECT_SIZE="-0.8798601462734688" ORDER="4" O_E="0.0" SE="0.7691958826905018" STUDY_ID="STD-Zabramski-2003" TOTAL_1="149" TOTAL_2="139" VAR="0.5916623059480202" WEIGHT="60.82993315391961"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6664518860826583" CI_START="0.2602357967170303" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2217927791963982" LOG_CI_START="-0.5846329643178945" LOG_EFFECT_SIZE="-0.18142009256074815" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3778531409253081" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="60" WEIGHT="100.0" Z="0.8818588700837707">
<NAME>Shunt revision</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6664518860826583" CI_START="0.2602357967170303" DF="0.0" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.2217927791963982" LOG_CI_START="-0.5846329643178945" LOG_EFFECT_SIZE="-0.18142009256074815" NO="1" P_CHI2="1.0" P_Z="0.3778531409253081" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="100.0" Z="0.8818588700837707">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="1.666451886082658" CI_START="0.2602357967170303" EFFECT_SIZE="0.6585365853658537" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.2217927791963981" LOG_CI_START="-0.5846329643178945" LOG_EFFECT_SIZE="-0.18142009256074815" ORDER="5" O_E="0.0" SE="0.47369847361210593" STUDY_ID="STD-Govender-2003" TOTAL_1="50" TOTAL_2="60" VAR="0.22439024390243903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Systemic antibiotic prophylaxis versus placebo or no antibiotic</NAME>
<DICH_OUTCOME CHI2="10.268566410588733" CI_END="0.7392880938170775" CI_START="0.36408383087155544" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5188090605556648" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.13118628802834648" LOG_CI_START="-0.43879860785316716" LOG_EFFECT_SIZE="-0.2849924479407568" METHOD="MH" NO="1" P_CHI2="0.8025149289965372" P_Q="0.0" P_Z="2.8158088040959345E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="869" WEIGHT="100.00000000000003" Z="3.6316811637966087">
<NAME>Shunt infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.019611482476252" CI_END="0.7329860699194466" CI_START="0.35876142425616764" DF="14.0" EFFECT_SIZE="0.512803204362289" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="92" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.13490427885764825" LOG_CI_START="-0.445194260536929" LOG_EFFECT_SIZE="-0.2900492696972886" NO="1" P_CHI2="0.7607483223020628" P_Z="2.4808882734058345E-4" STUDIES="15" TAU2="0.0" TOTAL_1="842" TOTAL_2="842" WEIGHT="98.94732006454993" Z="3.664224795606996">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="6" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="3.6631135127531294"/>
<DICH_DATA CI_END="0.7349754160399233" CI_START="0.06986357010428841" EFFECT_SIZE="0.22660098522167488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.13372718725153712" LOG_CI_START="-1.1557492252117405" LOG_EFFECT_SIZE="-0.6447382062316388" ORDER="7" O_E="0.0" SE="0.6003408041885033" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="62" TOTAL_2="60" VAR="0.36040908117369885" WEIGHT="15.180449998102825"/>
<DICH_DATA CI_END="1.6129855430575477" CI_START="0.09531409964660464" EFFECT_SIZE="0.39209726443769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20763047489146053" LOG_CI_START="-1.0208428501929112" LOG_EFFECT_SIZE="-0.4066061876507253" ORDER="8" O_E="0.0" SE="0.7216113121955928" STUDY_ID="STD-Blum-1989" TOTAL_1="50" TOTAL_2="50" VAR="0.5207228858886453" WEIGHT="7.503853473200138"/>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="9" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.092247310384672"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="10" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="6.614338927744802"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="11" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.085582120586637"/>
<DICH_DATA CI_END="3.4565747558262365" CI_START="0.12223082960605855" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.538645953867591" LOG_CI_START="-0.9128192405818797" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="12" O_E="0.0" SE="0.8525978400882076" STUDY_ID="STD-Odio-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.7269230769230768" WEIGHT="3.909954045957518"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="13" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.149685203688001"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="14" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.49155313077770524"/>
<DICH_DATA CI_END="5.98424303296385" CI_START="0.4700023865092637" EFFECT_SIZE="1.6770833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7770092228463495" LOG_CI_START="-0.3278999368617871" LOG_EFFECT_SIZE="0.22455464299228126" ORDER="15" O_E="0.0" SE="0.6490291098011092" STUDY_ID="STD-Schmidt-1985" TOTAL_1="79" TOTAL_2="73" VAR="0.42123878536922016" WEIGHT="4.32152815605831"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="16" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="22.66727474173932"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="17" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="4.846713869468174"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="18" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="7.490648803834404"/>
<DICH_DATA CI_END="6.009759478862473" CI_START="0.04704911124515943" EFFECT_SIZE="0.5317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7788570911220312" LOG_CI_START="-1.327448575955504" LOG_EFFECT_SIZE="-0.27429574241673643" ORDER="19" O_E="0.0" SE="1.2372543752225507" STUDY_ID="STD-Young-1987" TOTAL_1="64" TOTAL_2="69" VAR="1.5307983890073442" WEIGHT="2.160764078029155"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="20" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="8.769612692225133"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.298701093593795" CI_START="0.06413630700388791" DF="0.0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.2624202630689303" LOG_CI_START="-1.1928960505505064" LOG_EFFECT_SIZE="0.03476210625921191" NO="2" P_CHI2="1.0" P_Z="0.9557417856196668" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="27" WEIGHT="1.052679935450101" Z="0.05549792172754649">
<NAME>External shunts</NAME>
<DICH_DATA CI_END="18.298701093593795" CI_START="0.06413630700388791" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2624202630689303" LOG_CI_START="-1.1928960505505064" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="21" O_E="0.0" SE="1.4422649566318269" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="25" TOTAL_2="27" VAR="2.0801282051282053" WEIGHT="1.052679935450101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3146783349553743" CI_END="1.3553961676601984" CI_START="0.424146259728388" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7582125130616509" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.13206625335182903" LOG_CI_START="-0.3724843584076529" LOG_EFFECT_SIZE="-0.12020905252791195" METHOD="MH" NO="2" P_CHI2="0.85441423856886" P_Q="0.0" P_Z="0.3503442319582464" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="131" WEIGHT="99.99999999999999" Z="0.9339218230210116">
<NAME>Shunt revision</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3146783349553743" CI_END="1.3553961676601984" CI_START="0.424146259728388" DF="2.0" EFFECT_SIZE="0.7582125130616509" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="40" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.13206625335182903" LOG_CI_START="-0.3724843584076529" LOG_EFFECT_SIZE="-0.12020905252791195" NO="1" P_CHI2="0.85441423856886" P_Z="0.3503442319582464" STUDIES="3" TAU2="0.0" TOTAL_1="117" TOTAL_2="131" WEIGHT="99.99999999999999" Z="0.9339218230210116">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="1.6824623340502587" CI_START="0.22709988727080735" EFFECT_SIZE="0.6181318681318682" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.22594535028250198" LOG_CI_START="-0.6437830813578891" LOG_EFFECT_SIZE="-0.2089188655376935" ORDER="22" O_E="0.0" SE="0.5108827859707361" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.261001221001221" WEIGHT="37.441222570532915"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="23" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="10.511363636363635"/>
<DICH_DATA CI_END="1.9046798670387122" CI_START="0.4042433789065898" EFFECT_SIZE="0.8774703557312253" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.27982199121271417" LOG_CI_START="-0.39335708466307273" LOG_EFFECT_SIZE="-0.056767546725179266" ORDER="24" O_E="0.0" SE="0.3954287214596053" STUDY_ID="STD-Wang-1984" TOTAL_1="51" TOTAL_2="60" VAR="0.1563638737551781" WEIGHT="52.04741379310344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="371.2954299035151" CI_START="1.0182899904028875" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="19.444444444444443" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="2.5697196037376053" LOG_CI_START="0.007871474756333596" LOG_EFFECT_SIZE="1.2887955392469694" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.048608663170390004" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="79" WEIGHT="100.0" Z="1.9720082637095342">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="371.2954299035151" CI_START="1.0182899904028875" DF="0.0" EFFECT_SIZE="19.444444444444443" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="2.5697196037376053" LOG_CI_START="0.007871474756333596" LOG_EFFECT_SIZE="1.2887955392469694" NO="1" P_CHI2="1.0" P_Z="0.048608663170390004" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="79" WEIGHT="100.0" Z="1.9720082637095342">
<NAME>Internal shunts</NAME>
<DICH_DATA CI_END="371.2954299035148" CI_START="1.018289990402888" EFFECT_SIZE="19.444444444444443" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.569719603737605" LOG_CI_START="0.007871474756333785" LOG_EFFECT_SIZE="1.2887955392469694" ORDER="25" O_E="0.0" SE="1.5048422723163595" STUDY_ID="STD-Odio-1984" TOTAL_1="20" TOTAL_2="17" VAR="2.264550264550264" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.21878140210237" CI_END="0.7421090932618134" CI_START="0.3654452556813307" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5207689001183767" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.12953224685167702" LOG_CI_START="-0.4371776718831495" LOG_EFFECT_SIZE="-0.2833549593674133" METHOD="MH" NO="4" P_CHI2="0.816785274074747" P_Q="0.0" P_Z="3.0569455261049796E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="869" WEIGHT="100.00000000000003" Z="3.6104259645280012">
<NAME>Shunt infection (sensitivity analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.380462984443937" CI_END="1.3822138826097383" CI_START="0.4379327381617598" DF="6.0" EFFECT_SIZE="0.7780210217831391" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.14057525059976098" LOG_CI_START="-0.3585925874145308" LOG_EFFECT_SIZE="-0.10900866840738495" NO="1" P_CHI2="0.8815986234728687" P_Z="0.39197733413728264" STUDIES="7" TAU2="0.0" TOTAL_1="362" TOTAL_2="374" WEIGHT="30.283874322316528" Z="0.856036979189459">
<NAME>Class A studies</NAME>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="27" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.0956583309846084"/>
<DICH_DATA CI_END="3.4565747558262365" CI_START="0.12223082960605855" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.538645953867591" LOG_CI_START="-0.9128192405818797" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="28" O_E="0.0" SE="0.8525978400882076" STUDY_ID="STD-Odio-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.7269230769230768" WEIGHT="3.9142670689653407"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="29" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.153159583333191"/>
<DICH_DATA CI_END="5.98424303296385" CI_START="0.4700023865092637" EFFECT_SIZE="1.6770833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7770092228463495" LOG_CI_START="-0.3278999368617871" LOG_EFFECT_SIZE="0.22455464299228126" ORDER="30" O_E="0.0" SE="0.6490291098011092" STUDY_ID="STD-Schmidt-1985" TOTAL_1="79" TOTAL_2="73" VAR="0.42123878536922016" WEIGHT="4.326295181488008"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="31" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="4.852060220904954"/>
<DICH_DATA CI_END="6.009759478862473" CI_START="0.04704911124515943" EFFECT_SIZE="0.5317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7788570911220312" LOG_CI_START="-1.327448575955504" LOG_EFFECT_SIZE="-0.27429574241673643" ORDER="32" O_E="0.0" SE="1.2372543752225507" STUDY_ID="STD-Young-1987" TOTAL_1="64" TOTAL_2="69" VAR="1.5307983890073442" WEIGHT="2.163147590744004"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="33" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="8.779286345896423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.171501058885449" CI_END="0.6454970600255268" CI_START="0.25917801173248967" DF="7.0" EFFECT_SIZE="0.40902156984269616" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="64" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.1901057314263732" LOG_CI_START="-0.5864018461205509" LOG_EFFECT_SIZE="-0.38825378877346206" NO="2" P_CHI2="0.7598257069428808" P_Z="1.2284500372422122E-4" STUDIES="8" TAU2="0.0" TOTAL_1="505" TOTAL_2="495" WEIGHT="69.7161256776835" Z="3.8403780135187233">
<NAME>Class B + C studies</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="34" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="3.6671542489549025"/>
<DICH_DATA CI_END="0.8451858854166626" CI_START="0.10135438503580332" EFFECT_SIZE="0.2926829268292683" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.07304776426624811" LOG_CI_START="-0.9941574570779734" LOG_EFFECT_SIZE="-0.5336026106721107" ORDER="35" O_E="0.0" SE="0.5410643931241226" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="87" TOTAL_2="87" VAR="0.2927506775067751" WEIGHT="16.14072771254386"/>
<DICH_DATA CI_END="1.6129855430575477" CI_START="0.09531409964660464" EFFECT_SIZE="0.39209726443769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20763047489146053" LOG_CI_START="-1.0208428501929112" LOG_EFFECT_SIZE="-0.4066061876507253" ORDER="36" O_E="0.0" SE="0.7216113121955928" STUDY_ID="STD-Blum-1989" TOTAL_1="50" TOTAL_2="50" VAR="0.5207228858886453" WEIGHT="7.512130883189316"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="37" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="6.621635124999701"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="38" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.091191964701541"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="39" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.49209535708975183"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="40" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="22.69227873829187"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="41" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="7.498911647912547"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.019611482476252" CI_END="0.7329860699194468" CI_START="0.3587614242561677" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5128032043622891" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.1349042788576481" LOG_CI_START="-0.4451942605369289" LOG_EFFECT_SIZE="-0.2900492696972885" METHOD="MH" NO="5" P_CHI2="0.7607483223020628" P_Q="0.0" P_Z="2.4808882734058465E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="842" TOTAL_2="842" WEIGHT="100.0" Z="3.664224795606995">
<NAME>Shunt infection (internal shunts)</NAME>
<GROUP_LABEL_1>Placebo controlled</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7440286247735557" CI_END="0.7089071258532321" CI_START="0.3006710518010712" DF="8.0" EFFECT_SIZE="0.46167938134550224" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="68" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.14941065814763899" LOG_CI_START="-0.5219083831673441" LOG_EFFECT_SIZE="-0.3356595206574915" NO="1" P_CHI2="0.8794481990386586" P_Z="4.120142943660344E-4" STUDIES="9" TAU2="0.0" TOTAL_1="535" TOTAL_2="516" WEIGHT="73.7022584536771" Z="3.5322662522132715">
<NAME>Placebo controlled trials</NAME>
<DICH_DATA CI_END="0.7349754160399233" CI_START="0.06986357010428841" EFFECT_SIZE="0.22660098522167488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.13372718725153712" LOG_CI_START="-1.1557492252117405" LOG_EFFECT_SIZE="-0.6447382062316388" ORDER="42" O_E="0.0" SE="0.6003408041885033" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="62" TOTAL_2="60" VAR="0.36040908117369885" WEIGHT="15.341951644773813"/>
<DICH_DATA CI_END="1.6129855430575477" CI_START="0.09531409964660464" EFFECT_SIZE="0.39209726443769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20763047489146053" LOG_CI_START="-1.0208428501929112" LOG_EFFECT_SIZE="-0.4066061876507253" ORDER="50" O_E="0.0" SE="0.7216113121955928" STUDY_ID="STD-Blum-1989" TOTAL_1="50" TOTAL_2="50" VAR="0.5207228858886453" WEIGHT="7.583685407856297"/>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="43" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.1251450856550678"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="44" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.139686569852498"/>
<DICH_DATA CI_END="3.4565747558262365" CI_START="0.12223082960605855" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.538645953867591" LOG_CI_START="-0.9128192405818797" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="45" O_E="0.0" SE="0.8525978400882076" STUDY_ID="STD-Odio-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.7269230769230768" WEIGHT="3.9515512329255564"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="46" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.183194048745587"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="47" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="22.908427157958346"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="48" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="4.898277049147304"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="49" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="7.570340256762645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.473015779784126" CI_END="1.2566338133916326" CI_START="0.3425383009702734" DF="5.0" EFFECT_SIZE="0.656083235101283" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="8.642689859059454" ID="CMP-002.05.02" LOG_CI_END="0.09920874149469662" LOG_CI_START="-0.465290860755364" LOG_EFFECT_SIZE="-0.1830410596303337" NO="2" P_CHI2="0.3609139617124084" P_Z="0.2037105403632744" STUDIES="6" TAU2="0.0" TOTAL_1="307" TOTAL_2="326" WEIGHT="26.297741546322897" Z="1.271050973774053">
<NAME>Standard care controlled trials</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="51" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="3.7020846146853064"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="52" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="6.6847075023657325"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="53" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.49678266218532496"/>
<DICH_DATA CI_END="5.98424303296385" CI_START="0.4700023865092637" EFFECT_SIZE="1.6770833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7770092228463495" LOG_CI_START="-0.3278999368617871" LOG_EFFECT_SIZE="0.22455464299228126" ORDER="56" O_E="0.0" SE="0.6490291098011092" STUDY_ID="STD-Schmidt-1985" TOTAL_1="79" TOTAL_2="73" VAR="0.42123878536922016" WEIGHT="4.367503994286141"/>
<DICH_DATA CI_END="6.009759478862473" CI_START="0.04704911124515943" EFFECT_SIZE="0.5317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7788570911220312" LOG_CI_START="-1.327448575955504" LOG_EFFECT_SIZE="-0.27429574241673643" ORDER="55" O_E="0.0" SE="1.2372543752225507" STUDY_ID="STD-Young-1987" TOTAL_1="64" TOTAL_2="69" VAR="1.5307983890073442" WEIGHT="2.1837519971430703"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="54" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="8.86291077565732"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>VA versus VP shunts (subgroup analysis for systemic antibiotics)</NAME>
<DICH_OUTCOME CHI2="9.741052295345165" CI_END="0.7574336637996761" CI_START="0.35157928555405055" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5160406828664549" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.12065539676266454" LOG_CI_START="-0.4539767207273492" LOG_EFFECT_SIZE="-0.2873160587450068" METHOD="MH" NO="1" P_CHI2="0.6386662889083639" P_Q="0.0" P_Z="7.277740184913503E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="710" TOTAL_2="706" WEIGHT="100.00000000000001" Z="3.3788964991623005">
<NAME>Shunt infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6566081817475022" CI_END="0.9423189194567291" CI_START="0.22720829935230652" DF="2.0" EFFECT_SIZE="0.46271230709509614" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="45.304503501816406" ID="CMP-003.01.01" LOG_CI_END="-0.025802089224427793" LOG_CI_START="-0.6435758089773915" LOG_EFFECT_SIZE="-0.3346889491009096" NO="1" P_CHI2="0.16068592101453982" P_Z="0.033696520885693436" STUDIES="3" TAU2="0.0" TOTAL_1="171" TOTAL_2="157" WEIGHT="30.6912789673834" Z="2.123684660861443">
<NAME>Ventriculoatrial shunts</NAME>
<DICH_DATA CI_END="0.7349754160399233" CI_START="0.06986357010428841" EFFECT_SIZE="0.22660098522167488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.13372718725153712" LOG_CI_START="-1.1557492252117405" LOG_EFFECT_SIZE="-0.6447382062316388" ORDER="57" O_E="0.0" SE="0.6003408041885033" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="62" TOTAL_2="60" VAR="0.36040908117369885" WEIGHT="17.781878918992057"/>
<DICH_DATA CI_END="10.09813402051907" CI_START="0.29873048748266623" EFFECT_SIZE="1.736842105263158" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.004241130271693" LOG_CI_START="-0.5247204524215761" LOG_EFFECT_SIZE="0.23976033892505855" ORDER="58" O_E="0.0" SE="0.8981196021559236" STUDY_ID="STD-Schmidt-1985" TOTAL_1="42" TOTAL_2="35" VAR="0.8066188197767145" WEIGHT="2.6369647069428437"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="59" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="10.2724353414485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.947941912158669" CI_END="0.8513218589383402" CI_START="0.3420893129596767" DF="9.0" EFFECT_SIZE="0.5396555473927528" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="55" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.06990621531616366" LOG_CI_START="-0.46586049317868533" LOG_EFFECT_SIZE="-0.2678833542474245" NO="2" P_CHI2="0.7451170304882047" P_Z="0.008000893634959035" STUDIES="10" TAU2="0.0" TOTAL_1="539" TOTAL_2="549" WEIGHT="69.30872103261662" Z="2.652032094296682">
<NAME>Ventriculoperitoneal shunts</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="60" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="4.290850466121907"/>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="61" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.622156607196161"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="62" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="7.747818671846539"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="63" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.9570833217832195"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="64" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.689437462784066"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="65" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.5757891402977511"/>
<DICH_DATA CI_END="10.096541298373351" CI_START="0.24983717442797626" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.004172626031877" LOG_CI_START="-0.6023429404704503" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="66" O_E="0.0" SE="0.9436751961437757" STUDY_ID="STD-Schmidt-1985" TOTAL_1="37" TOTAL_2="38" VAR="0.8905228758169935" WEIGHT="2.4223065272899524"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="67" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="26.55169872642173"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="68" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="5.677280923335826"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="69" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="8.774299185539457"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Children versus all ages (subgroup analysis for sytemic antibiotics)</NAME>
<DICH_OUTCOME CHI2="9.21878140210237" CI_END="0.7421090932618134" CI_START="0.3654452556813307" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5207689001183767" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.12953224685167702" LOG_CI_START="-0.4371776718831495" LOG_EFFECT_SIZE="-0.2833549593674133" METHOD="MH" NO="1" P_CHI2="0.816785274074747" P_Q="0.0" P_Z="3.0569455261049796E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="869" WEIGHT="100.00000000000001" Z="3.6104259645280012">
<NAME>Shunt infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0533456605233016" CI_END="0.8271535564571614" CI_START="0.3273413024073052" DF="7.0" EFFECT_SIZE="0.5203475016385892" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="55" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.08241385860775859" LOG_CI_START="-0.48499919397123514" LOG_EFFECT_SIZE="-0.2837065262894969" NO="1" P_CHI2="0.956828844136673" P_Z="0.005737489736171082" STUDIES="8" TAU2="0.0" TOTAL_1="479" TOTAL_2="478" WEIGHT="58.38115435625366" Z="2.7624184234348372">
<NAME>Children</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="70" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="3.6671542489549025"/>
<DICH_DATA CI_END="1.6129855430575477" CI_START="0.09531409964660464" EFFECT_SIZE="0.39209726443769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20763047489146053" LOG_CI_START="-1.0208428501929112" LOG_EFFECT_SIZE="-0.4066061876507253" ORDER="71" O_E="0.0" SE="0.7216113121955928" STUDY_ID="STD-Blum-1989" TOTAL_1="50" TOTAL_2="50" VAR="0.5207228858886453" WEIGHT="7.512130883189316"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="72" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.091191964701541"/>
<DICH_DATA CI_END="3.4565747558262365" CI_START="0.12223082960605855" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.538645953867591" LOG_CI_START="-0.9128192405818797" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="73" O_E="0.0" SE="0.8525978400882076" STUDY_ID="STD-Odio-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.7269230769230768" WEIGHT="3.9142670689653407"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="74" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.153159583333191"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="75" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="22.69227873829187"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="76" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="4.852060220904954"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="77" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="7.498911647912547"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.1651709951614055" CI_END="0.9028551953141603" CI_START="0.301062974361632" DF="6.0" EFFECT_SIZE="0.5213600200620808" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" I2="16.26159370025137" ID="CMP-004.01.02" LOG_CI_END="-0.044381898544621816" LOG_CI_START="-0.5213426520567429" LOG_EFFECT_SIZE="-0.2828622753006823" NO="2" P_CHI2="0.30584241243784727" P_Z="0.020086988575595564" STUDIES="7" TAU2="0.0" TOTAL_1="388" TOTAL_2="391" WEIGHT="41.618845643746354" Z="2.3247190385877405">
<NAME>All ages</NAME>
<DICH_DATA CI_END="0.8451858854166626" CI_START="0.10135438503580332" EFFECT_SIZE="0.2926829268292683" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.07304776426624811" LOG_CI_START="-0.9941574570779734" LOG_EFFECT_SIZE="-0.5336026106721107" ORDER="78" O_E="0.0" SE="0.5410643931241226" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="87" TOTAL_2="87" VAR="0.2927506775067751" WEIGHT="16.14072771254386"/>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="79" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.0956583309846084"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="80" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="6.621635124999701"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="81" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.49209535708975183"/>
<DICH_DATA CI_END="5.98424303296385" CI_START="0.4700023865092637" EFFECT_SIZE="1.6770833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7770092228463495" LOG_CI_START="-0.3278999368617871" LOG_EFFECT_SIZE="0.22455464299228126" ORDER="82" O_E="0.0" SE="0.6490291098011092" STUDY_ID="STD-Schmidt-1985" TOTAL_1="79" TOTAL_2="73" VAR="0.42123878536922016" WEIGHT="4.326295181488008"/>
<DICH_DATA CI_END="6.009759478862473" CI_START="0.04704911124515943" EFFECT_SIZE="0.5317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7788570911220312" LOG_CI_START="-1.327448575955504" LOG_EFFECT_SIZE="-0.27429574241673643" ORDER="83" O_E="0.0" SE="1.2372543752225507" STUDY_ID="STD-Young-1987" TOTAL_1="64" TOTAL_2="69" VAR="1.5307983890073442" WEIGHT="2.163147590744004"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="84" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="8.779286345896423"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Periprocedural versus continuous antibiotics (subgroup analysis for systemic antibiotics)</NAME>
<DICH_OUTCOME CHI2="10.268566410588729" CI_END="0.7392880938170773" CI_START="0.3640838308715554" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5188090605556647" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.13118628802834661" LOG_CI_START="-0.4387986078531672" LOG_EFFECT_SIZE="-0.2849924479407569" METHOD="MH" NO="1" P_CHI2="0.8025149289965374" P_Q="0.0" P_Z="2.8158088040959047E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="867" TOTAL_2="869" WEIGHT="100.00000000000001" Z="3.6316811637966113">
<NAME>Shunt infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.059368197415896" CI_END="0.8258941074191188" CI_START="0.34124974837266225" DF="11.0" EFFECT_SIZE="0.5308824317485358" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="60" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-0.08307563247580765" LOG_CI_START="-0.4669276601868053" LOG_EFFECT_SIZE="-0.2750016463313065" NO="1" P_CHI2="0.6164124449542432" P_Z="0.0049797765253125756" STUDIES="12" TAU2="0.0" TOTAL_1="571" TOTAL_2="606" WEIGHT="63.703814398389554" Z="2.8083390660340113">
<NAME>Periprocedural antibiotics</NAME>
<DICH_DATA CI_END="3.212298602702962" CI_START="0.03792938568519993" EFFECT_SIZE="0.3490566037735849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5068159087980033" LOG_CI_START="-1.421024191193554" LOG_EFFECT_SIZE="-0.45710414119777526" ORDER="85" O_E="0.0" SE="1.1324228176974427" STUDY_ID="STD-Bayston-1975" TOTAL_1="54" TOTAL_2="78" VAR="1.2823814380418155" WEIGHT="3.663113512753129"/>
<DICH_DATA CI_END="0.7349754160399233" CI_START="0.06986357010428841" EFFECT_SIZE="0.22660098522167488" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.13372718725153712" LOG_CI_START="-1.1557492252117405" LOG_EFFECT_SIZE="-0.6447382062316388" ORDER="86" O_E="0.0" SE="0.6003408041885033" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="62" TOTAL_2="60" VAR="0.36040908117369885" WEIGHT="15.180449998102821"/>
<DICH_DATA CI_END="1.6129855430575477" CI_START="0.09531409964660464" EFFECT_SIZE="0.39209726443769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20763047489146053" LOG_CI_START="-1.0208428501929112" LOG_EFFECT_SIZE="-0.4066061876507253" ORDER="87" O_E="0.0" SE="0.7216113121955928" STUDY_ID="STD-Blum-1989" TOTAL_1="50" TOTAL_2="50" VAR="0.5207228858886453" WEIGHT="7.503853473200136"/>
<DICH_DATA CI_END="3.7378891576615425" CI_START="0.03779959051318559" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5726264187844705" LOG_CI_START="-1.4225129048936522" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="88" O_E="0.0" SE="1.1719547148274612" STUDY_ID="STD-Bullock-1988" TOTAL_1="48" TOTAL_2="56" VAR="1.373477853606316" WEIGHT="3.0922473103846717"/>
<DICH_DATA CI_END="1.2262968682263318" CI_START="0.015514163630704642" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0885956191428248" LOG_CI_START="-1.809271632284812" LOG_EFFECT_SIZE="-0.8603380065709937" ORDER="89" O_E="0.0" SE="1.1148166180830026" STUDY_ID="STD-Djindjian-1986" TOTAL_1="30" TOTAL_2="30" VAR="1.2428160919540232" WEIGHT="6.614338927744801"/>
<DICH_DATA CI_END="3.4565747558262365" CI_START="0.12223082960605855" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.538645953867591" LOG_CI_START="-0.9128192405818797" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="90" O_E="0.0" SE="0.8525978400882076" STUDY_ID="STD-Odio-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.7269230769230768" WEIGHT="3.9099540459575177"/>
<DICH_DATA CI_END="4.290027606249014" CI_START="0.10359943693533584" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.632460086870747" LOG_CI_START="-0.9846426049821094" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="91" O_E="0.0" SE="0.949894125981792" STUDY_ID="STD-Rieder-1987" TOTAL_1="31" TOTAL_2="32" VAR="0.9022988505747126" WEIGHT="3.1496852036880005"/>
<DICH_DATA CI_END="93.30013904772645" CI_START="0.1298004496413997" EFFECT_SIZE="3.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9698822909878217" LOG_CI_START="-0.8867238030946596" LOG_EFFECT_SIZE="0.541579243946581" ORDER="92" O_E="0.0" SE="1.6779845600922692" STUDY_ID="STD-Rocca-1992" TOTAL_1="13" TOTAL_2="14" VAR="2.815632183908046" WEIGHT="0.4915531307777051"/>
<DICH_DATA CI_END="5.98424303296385" CI_START="0.4700023865092637" EFFECT_SIZE="1.6770833333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7770092228463495" LOG_CI_START="-0.3278999368617871" LOG_EFFECT_SIZE="0.22455464299228126" ORDER="93" O_E="0.0" SE="0.6490291098011092" STUDY_ID="STD-Schmidt-1985" TOTAL_1="79" TOTAL_2="73" VAR="0.42123878536922016" WEIGHT="4.321528156058309"/>
<DICH_DATA CI_END="3.691838695731324" CI_START="0.23993820472523514" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5672427175206769" LOG_CI_START="-0.6199005949653751" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="94" O_E="0.0" SE="0.6973338582084779" STUDY_ID="STD-Wang-1984" TOTAL_1="55" TOTAL_2="65" VAR="0.48627450980392156" WEIGHT="4.846713869468173"/>
<DICH_DATA CI_END="6.009759478862473" CI_START="0.04704911124515943" EFFECT_SIZE="0.5317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7788570911220312" LOG_CI_START="-1.327448575955504" LOG_EFFECT_SIZE="-0.27429574241673643" ORDER="95" O_E="0.0" SE="1.2372543752225507" STUDY_ID="STD-Young-1987" TOTAL_1="64" TOTAL_2="69" VAR="1.5307983890073442" WEIGHT="2.1607640780291546"/>
<DICH_DATA CI_END="1.7634085734515133" CI_START="0.1680394407103559" EFFECT_SIZE="0.5443548387096774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24635294794181348" LOG_CI_START="-0.7745887726042339" LOG_EFFECT_SIZE="-0.2641179123312102" ORDER="96" O_E="0.0" SE="0.5997062203917707" STUDY_ID="STD-Zentner-1995" TOTAL_1="67" TOTAL_2="62" VAR="0.35964755077658306" WEIGHT="8.769612692225131"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1682882084211301" CI_END="0.8993714604717133" CI_START="0.2753307625622442" DF="3.0" EFFECT_SIZE="0.4976189606902013" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="33" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.04606089790695354" LOG_CI_START="-0.5601452624001658" LOG_EFFECT_SIZE="-0.3031030801535597" NO="2" P_CHI2="0.7606197702307124" P_Z="0.020822835133156557" STUDIES="4" TAU2="0.0" TOTAL_1="296" TOTAL_2="263" WEIGHT="36.29618560161046" Z="2.311181439216785">
<NAME>Continuous antibiotics</NAME>
<DICH_DATA CI_END="18.298701093593795" CI_START="0.06413630700388791" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2624202630689303" LOG_CI_START="-1.1928960505505064" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="97" O_E="0.0" SE="1.4422649566318269" STUDY_ID="STD-Blomstedt-1985" TOTAL_1="25" TOTAL_2="27" VAR="2.0801282051282053" WEIGHT="1.052679935450101"/>
<DICH_DATA CI_END="2.2748146712331647" CI_START="0.07466273874002474" EFFECT_SIZE="0.4121212121212121" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3569460205362841" LOG_CI_START="-1.1268960835516242" LOG_EFFECT_SIZE="-0.38497503150767" ORDER="98" O_E="0.0" SE="0.8716161970781133" STUDY_ID="STD-Haines-1982" TOTAL_1="35" TOTAL_2="39" VAR="0.7597147950089126" WEIGHT="5.085582120586636"/>
<DICH_DATA CI_END="1.170521820615971" CI_START="0.2789615763617851" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06837951413241018" LOG_CI_START="-0.5544556115049991" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="99" O_E="0.0" SE="0.3658564358830095" STUDY_ID="STD-Walters-1992" TOTAL_1="130" TOTAL_2="113" VAR="0.13385093167701864" WEIGHT="22.667274741739316"/>
<DICH_DATA CI_END="1.272158286372063" CI_START="0.049129106550284164" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10454115110890018" LOG_CI_START="-1.3086611337648248" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="100" O_E="0.0" SE="0.8301220175989575" STUDY_ID="STD-Yogev-1985" TOTAL_1="106" TOTAL_2="84" VAR="0.689102564102564" WEIGHT="7.490648803834403"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan">
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-09-01 21:06:03 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of trials of systemic antibiotics for shunt infection</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-01 21:05:45 +0200" MODIFIED_BY="Karen Hovhannisyan">
<APPENDIX ID="APP-01" MODIFIED="2008-09-01 21:05:12 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="1">
<TITLE MODIFIED="2008-09-01 21:03:20 +0200" MODIFIED_BY="Karen Hovhannisyan">MEDLINE and CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-01 21:05:12 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TABLE COLS="2" ROWS="52">
<TR>
<TH>
<P>Number</P>
</TH>
<TH>
<P>Search</P>
</TH>
</TR>
<TR>
<TD>
<P>1.</P>
</TD>
<TD>
<P>exp Anti-Infective Agents/</P>
</TD>
</TR>
<TR>
<TD>
<P>2.</P>
</TD>
<TD>
<P>Antibiotic Prophylaxis/</P>
</TD>
</TR>
<TR>
<TD>
<P>3.</P>
</TD>
<TD>
<P>antibiotic$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>4.</P>
</TD>
<TD>
<P>antimicrob$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>5.</P>
</TD>
<TD>
<P>antibacter$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>6.</P>
</TD>
<TD>
<P>Bacteriocid$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>7.</P>
</TD>
<TD>
<P>OR/1-6</P>
</TD>
</TR>
<TR>
<TD>
<P>8.</P>
</TD>
<TD>
<P>(brain or intracran$ or CNS or (nerv$ and system)).tw</P>
</TD>
</TR>
<TR>
<TD>
<P>9.</P>
</TD>
<TD>
<P>exp Central Nervous System Infections/</P>
</TD>
</TR>
<TR>
<TD>
<P>10.</P>
</TD>
<TD>
<P>exp Infection/</P>
</TD>
</TR>
<TR>
<TD>
<P>11.</P>
</TD>
<TD>
<P>infect$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>12.</P>
</TD>
<TD>
<P>meningit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>13.</P>
</TD>
<TD>
<P>Empyem$ and subdura$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>14.</P>
</TD>
<TD>
<P>Encephalit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>15.</P>
</TD>
<TD>
<P>Meningoencephalit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>16.</P>
</TD>
<TD>
<P>Encephalomyelit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>17.</P>
</TD>
<TD>
<P>Arachnoidit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>18.</P>
</TD>
<TD>
<P>Subdura$ and effusi$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>19.</P>
</TD>
<TD>
<P>Ventriculit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>20.</P>
</TD>
<TD>
<P>Ventricul$ and debri$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>21.</P>
</TD>
<TD>
<P>Peritonitis/</P>
</TD>
</TR>
<TR>
<TD>
<P>22.</P>
</TD>
<TD>
<P>Peritonit$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>23.</P>
</TD>
<TD>
<P>Abdomin$ and abscess$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>24.</P>
</TD>
<TD>
<P>Septicem$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>25.</P>
</TD>
<TD>
<P>bacteriem$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>26.</P>
</TD>
<TD>
<P>OR /8-25</P>
</TD>
</TR>
<TR>
<TD>
<P>27.</P>
</TD>
<TD>
<P>Catheters, Indwelling/</P>
</TD>
</TR>
<TR>
<TD>
<P>28.</P>
</TD>
<TD>
<P>.Catheter$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>29.</P>
</TD>
<TD>
<P>Impregnat$ and (cathet$ or devic$).tw</P>
</TD>
</TR>
<TR>
<TD>
<P>30.</P>
</TD>
<TD>
<P>exp Cerebrospinal Fluid Shunts /</P>
</TD>
</TR>
<TR>
<TD>
<P>31.</P>
</TD>
<TD>
<P>exp Cerebral Ventricles/</P>
</TD>
</TR>
<TR>
<TD>
<P>32.</P>
</TD>
<TD>
<P>Injections, Intraventricular/</P>
</TD>
</TR>
<TR>
<TD>
<P>33.</P>
</TD>
<TD>
<P>Cerebrospinal Fluid/</P>
</TD>
</TR>
<TR>
<TD>
<P>34.</P>
</TD>
<TD>
<P>exp Intracranial Hypertension/</P>
</TD>
</TR>
<TR>
<TD>
<P>35.</P>
</TD>
<TD>
<P>Hydrocephal$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>36.</P>
</TD>
<TD>
<P>CSF and shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>37.</P>
</TD>
<TD>
<P>cerebrospin$ and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>38.</P>
</TD>
<TD>
<P>Ventriculostom$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>39.</P>
</TD>
<TD>
<P>Ventricul$ and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>40.</P>
</TD>
<TD>
<P>Ventriculoperiton$ and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>41.</P>
</TD>
<TD>
<P>Ventriculoatria$ and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>42.</P>
</TD>
<TD>
<P>ventricul$ and drain$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>43.</P>
</TD>
<TD>
<P>Ventriculocisternost$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>44.</P>
</TD>
<TD>
<P>Ventriculopleura$.tw and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>45.</P>
</TD>
<TD>
<P>Bladder$.tw and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>46.</P>
</TD>
<TD>
<P>Ureter$.tw and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>47.</P>
</TD>
<TD>
<P>Gall bladder$.tw and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>48.</P>
</TD>
<TD>
<P>Sinus$.tw and Shunt$.tw</P>
</TD>
</TR>
<TR>
<TD>
<P>49.</P>
</TD>
<TD>
<P>OR /27-48</P>
</TD>
</TR>
<TR>
<TD>
<P>50.</P>
</TD>
<TD>
<P>7 AND 26 AND 49</P>
</TD>
</TR>
<TR>
<TD>
<P>51.</P>
</TD>
<TD>
<P>limit 50 to human</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-09-01 21:05:22 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="2">
<TITLE MODIFIED="2008-09-01 21:03:43 +0200" MODIFIED_BY="Karen Hovhannisyan">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-01 21:05:22 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TABLE COLS="2" ROWS="86">
<TR>
<TH>
<P>Number</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>1.</P>
</TD>
<TD>
<P>explode "antiinfective-agent" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>2.</P>
</TD>
<TD>
<P>explode "antibiotic-prophylaxis" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>3.</P>
</TD>
<TD>
<P>antibiotic*</P>
</TD>
</TR>
<TR>
<TD>
<P>4.</P>
</TD>
<TD>
<P>antimicrob*</P>
</TD>
</TR>
<TR>
<TD>
<P>5.</P>
</TD>
<TD>
<P>antibacter*</P>
</TD>
</TR>
<TR>
<TD>
<P>6.</P>
</TD>
<TD>
<P>Bacteriocid*</P>
</TD>
</TR>
<TR>
<TD>
<P>7.</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6</P>
</TD>
</TR>
<TR>
<TD>
<P>8.</P>
</TD>
<TD>
<P>explode "indwelling-catheter" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>9.</P>
</TD>
<TD>
<P>Catheter*</P>
</TD>
</TR>
<TR>
<TD>
<P>10.</P>
</TD>
<TD>
<P>Impregnat* and (cathet* or devic*)</P>
</TD>
</TR>
<TR>
<TD>
<P>11.</P>
</TD>
<TD>
<P>brain or intracran* or CNS or (nerv* and system)</P>
</TD>
</TR>
<TR>
<TD>
<P>12.</P>
</TD>
<TD>
<P>#8 or #9 or #10</P>
</TD>
</TR>
<TR>
<TD>
<P>13.</P>
</TD>
<TD>
<P>#11 and #12</P>
</TD>
</TR>
<TR>
<TD>
<P>14.</P>
</TD>
<TD>
<P>#7 or #13</P>
</TD>
</TR>
<TR>
<TD>
<P>15.</P>
</TD>
<TD>
<P>explode "central-nervous-system-infection" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>16.</P>
</TD>
<TD>
<P>explode "infection-" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>17.</P>
</TD>
<TD>
<P>infect*</P>
</TD>
</TR>
<TR>
<TD>
<P>18.</P>
</TD>
<TD>
<P>meningit*</P>
</TD>
</TR>
<TR>
<TD>
<P>19.</P>
</TD>
<TD>
<P>Empyem* and subdura*</P>
</TD>
</TR>
<TR>
<TD>
<P>20.</P>
</TD>
<TD>
<P>Encephalit*</P>
</TD>
</TR>
<TR>
<TD>
<P>21.</P>
</TD>
<TD>
<P>Meningoencephalit*</P>
</TD>
</TR>
<TR>
<TD>
<P>22.</P>
</TD>
<TD>
<P>Encephalomyelit*</P>
</TD>
</TR>
<TR>
<TD>
<P>23.</P>
</TD>
<TD>
<P>Arachnoidit*</P>
</TD>
</TR>
<TR>
<TD>
<P>24.</P>
</TD>
<TD>
<P>Subdura* and effusi*</P>
</TD>
</TR>
<TR>
<TD>
<P>25.</P>
</TD>
<TD>
<P>Ventriculit*</P>
</TD>
</TR>
<TR>
<TD>
<P>26.</P>
</TD>
<TD>
<P>Ventricul* and debri*</P>
</TD>
</TR>
<TR>
<TD>
<P>27.</P>
</TD>
<TD>
<P>"peritonitis-" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>28.</P>
</TD>
<TD>
<P>Peritonit*</P>
</TD>
</TR>
<TR>
<TD>
<P>29.</P>
</TD>
<TD>
<P>Abdomin* and abscess*</P>
</TD>
</TR>
<TR>
<TD>
<P>30.</P>
</TD>
<TD>
<P>Septicem*</P>
</TD>
</TR>
<TR>
<TD>
<P>31.</P>
</TD>
<TD>
<P>bacteriem*</P>
</TD>
</TR>
<TR>
<TD>
<P>32.</P>
</TD>
<TD>
<P>#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31</P>
</TD>
</TR>
<TR>
<TD>
<P>33.</P>
</TD>
<TD>
<P>explode "cerebrospinal-fluid" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>34.</P>
</TD>
<TD>
<P>explode "brain-ventricle" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>35.</P>
</TD>
<TD>
<P>"intracerebroventricular-drug-administration" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>36.</P>
</TD>
<TD>
<P>"cerebrospinal-fluid" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>37.</P>
</TD>
<TD>
<P>explode "intracranial-hypertension" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>38.</P>
</TD>
<TD>
<P>Hydrocephal*</P>
</TD>
</TR>
<TR>
<TD>
<P>39.</P>
</TD>
<TD>
<P>CSF and shunt</P>
</TD>
</TR>
<TR>
<TD>
<P>40.</P>
</TD>
<TD>
<P>cerebrospin* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>41.</P>
</TD>
<TD>
<P>Ventriculostom*</P>
</TD>
</TR>
<TR>
<TD>
<P>42.</P>
</TD>
<TD>
<P>Ventricul* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>43.</P>
</TD>
<TD>
<P>Ventriculoperiton* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>44.</P>
</TD>
<TD>
<P>Ventriculoatria* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>45.</P>
</TD>
<TD>
<P>ventricul* and drain*</P>
</TD>
</TR>
<TR>
<TD>
<P>46.</P>
</TD>
<TD>
<P>Ventriculocisternost*</P>
</TD>
</TR>
<TR>
<TD>
<P>47.</P>
</TD>
<TD>
<P>Ventriculopleura* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>48.</P>
</TD>
<TD>
<P>Bladder* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>49.</P>
</TD>
<TD>
<P>Ureter* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>50.</P>
</TD>
<TD>
<P>Gall bladder* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>51.</P>
</TD>
<TD>
<P>Sinus* and Shunt*</P>
</TD>
</TR>
<TR>
<TD>
<P>52.</P>
</TD>
<TD>
<P>#33 or #4 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51</P>
</TD>
</TR>
<TR>
<TD>
<P>53.</P>
</TD>
<TD>
<P>#14 and #32 and #52</P>
</TD>
</TR>
<TR>
<TD>
<P>54.</P>
</TD>
<TD>
<P>explode shunt-infection/ all subheadings</P>
</TD>
</TR>
<TR>
<TD>
<P>55.</P>
</TD>
<TD>
<P>Shunt revision</P>
</TD>
</TR>
<TR>
<TD>
<P>56.</P>
</TD>
<TD>
<P>infection* near ((shunt equipment*) or (overlying wound) or CSF or (distal drainage route))</P>
</TD>
</TR>
<TR>
<TD>
<P>57.</P>
</TD>
<TD>
<P>explode adverse-drug-reaction/ all subheadings</P>
</TD>
</TR>
<TR>
<TD>
<P>58.</P>
</TD>
<TD>
<P>#54 or #55 or #56 or #57</P>
</TD>
</TR>
<TR>
<TD>
<P>59.</P>
</TD>
<TD>
<P>#53 and #58</P>
</TD>
</TR>
<TR>
<TD>
<P>60.</P>
</TD>
<TD>
<P>explode "randomized-controlled-trial" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>61.</P>
</TD>
<TD>
<P>(randomi?ed controlled trial*) in TI, AB</P>
</TD>
</TR>
<TR>
<TD>
<P>62.</P>
</TD>
<TD>
<P>random*</P>
</TD>
</TR>
<TR>
<TD>
<P>63.</P>
</TD>
<TD>
<P>explode "randomization-" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>64.</P>
</TD>
<TD>
<P>randomi?ation</P>
</TD>
</TR>
<TR>
<TD>
<P>65.</P>
</TD>
<TD>
<P>explode "clinical-trial" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>66.</P>
</TD>
<TD>
<P>explode multicenter-study / all subheadings</P>
</TD>
</TR>
<TR>
<TD>
<P>67.</P>
</TD>
<TD>
<P>multi?cent*</P>
</TD>
</TR>
<TR>
<TD>
<P>68.</P>
</TD>
<TD>
<P>explode phase-4-clinical-trial / all subheadings or explode double-blind-procedure / all subheadings or explode single-blind-procedure / all subheadings</P>
</TD>
</TR>
<TR>
<TD>
<P>69.</P>
</TD>
<TD>
<P>(RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI, AB, TW</P>
</TD>
</TR>
<TR>
<TD>
<P>70.</P>
</TD>
<TD>
<P>((SINGL* or DOUBL* or TREBL* or TRIPL*) near (BLIND* or MASK*)) in TI,AB</P>
</TD>
</TR>
<TR>
<TD>
<P>71.</P>
</TD>
<TD>
<P>explode "follow-up" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>72.</P>
</TD>
<TD>
<P>(follow?up near stud*) in TI, AB</P>
</TD>
</TR>
<TR>
<TD>
<P>73.</P>
</TD>
<TD>
<P>evaluation stud*</P>
</TD>
</TR>
<TR>
<TD>
<P>74.</P>
</TD>
<TD>
<P>explode "prospective-study" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>75.</P>
</TD>
<TD>
<P>prospective?stud*</P>
</TD>
</TR>
<TR>
<TD>
<P>76.</P>
</TD>
<TD>
<P>research near design*</P>
</TD>
</TR>
<TR>
<TD>
<P>77.</P>
</TD>
<TD>
<P>explode "comparative-study" / all SUBHEADINGS in DEM,DER,DRM,DRR</P>
</TD>
</TR>
<TR>
<TD>
<P>78.</P>
</TD>
<TD>
<P>clinic* near trial*</P>
</TD>
</TR>
<TR>
<TD>
<P>79.</P>
</TD>
<TD>
<P>#60 or #61 or #62 or #63 or #62 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78</P>
</TD>
</TR>
<TR>
<TD>
<P>80.</P>
</TD>
<TD>
<P>(human) in DER</P>
</TD>
</TR>
<TR>
<TD>
<P>81.</P>
</TD>
<TD>
<P>(animal or nonhuman) in DER</P>
</TD>
</TR>
<TR>
<TD>
<P>82.</P>
</TD>
<TD>
<P>#80 and #81</P>
</TD>
</TR>
<TR>
<TD>
<P>83.</P>
</TD>
<TD>
<P>#81 not #82</P>
</TD>
</TR>
<TR>
<TD>
<P>84.</P>
</TD>
<TD>
<P>#79 not #83</P>
</TD>
</TR>
<TR>
<TD>
<P>85.</P>
</TD>
<TD>
<P>#84 and #59</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-09-01 21:05:45 +0200" MODIFIED_BY="Karen Hovhannisyan" NO="3">
<TITLE MODIFIED="2008-09-01 21:04:06 +0200" MODIFIED_BY="Karen Hovhannisyan">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-01 21:05:45 +0200" MODIFIED_BY="Karen Hovhannisyan">
<TABLE COLS="2" ROWS="11">
<TR>
<TH>
<P>Number</P>
</TH>
<TH>
<P>key words</P>
</TH>
</TR>
<TR>
<TD>
<P>1.</P>
</TD>
<TD>
<P>ant$ AND prophylaxis</P>
</TD>
</TR>
<TR>
<TD>
<P>2.</P>
</TD>
<TD>
<P>ventriculoperit$</P>
</TD>
</TR>
<TR>
<TD>
<P>3.</P>
</TD>
<TD>
<P>cns AND infect$</P>
</TD>
</TR>
<TR>
<TD>
<P>4.</P>
</TD>
<TD>
<P>ventricul$ AND infect$</P>
</TD>
</TR>
<TR>
<TD>
<P>5.</P>
</TD>
<TD>
<P>hydroceph$</P>
</TD>
</TR>
<TR>
<TD>
<P>6.</P>
</TD>
<TD>
<P>impregnat$</P>
</TD>
</TR>
<TR>
<TD>
<P>7.</P>
</TD>
<TD>
<P>csf AND shunt$</P>
</TD>
</TR>
<TR>
<TD>
<P>8.</P>
</TD>
<TD>
<P>cerebrosp$ AND shunt$</P>
</TD>
</TR>
<TR>
<TD>
<P>9.</P>
</TD>
<TD>
<P>infect$ AND shunt</P>
</TD>
</TR>
<TR>
<TD>
<P>10.</P>
</TD>
<TD>
<P>randomized OR randomised</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>